1
|
Kim J, Sookram G, Godecke E, Brogan E, Armstrong E, Ellery F, Rai T, Rose ML, Ciccone N, Middleton S, Holland A, Hankey GJ, Bernhardt J, Cadilhac DA. Economic evaluation of the Very Early Rehabilitation in SpEech (VERSE) intervention. Top Stroke Rehabil 2024; 31:157-166. [PMID: 37415422 DOI: 10.1080/10749357.2023.2229039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 06/18/2023] [Indexed: 07/08/2023]
Abstract
INTRODUCTION There is limited evidence on the costs and outcomes of patients with aphasia after stroke. The aim of this study was to estimate costs in patients with aphasia after stroke according to the aphasia therapies provided. METHODS A three-arm, prospective, randomized, parallel group, open-label, blinded endpoint assessment trial conducted in Australia and New Zealand. Usual ward-based care (Usual Care) was compared to additional usual ward-based therapy (Usual Care Plus) and a prescribed and structured aphasia therapy program in addition to Usual Care (the VERSE intervention). Information about healthcare utilization and productivity were collected to estimate costs in Australian dollars for 2017-18. Multivariable regression models with bootstrapping were used to estimate differences in costs and outcomes (clinically meaningful change in aphasia severity measured by the WAB-R-AQ). RESULTS Overall, 202/246 (82%) participants completed follow-up at 26 weeks. Median costs per person were $23,322 (Q1 5,367, Q3 52,669, n = 63) for Usual Care, $26,923 (Q1 7,303, Q3 76,174, n = 70) for Usual Care Plus and $31,143 (Q1 7,001. Q3 62,390, n = 69) for VERSE. No differences in costs and outcomes were detected between groups. Usual Care Plus was inferior (i.e. more costly and less effective) in 64% of iterations, and in 18% was less costly and less effective compared to Usual Care. VERSE was inferior in 65% of samples and less costly and less effective in 12% compared to Usual Care. CONCLUSION There was limited evidence that additional intensively delivered aphasia therapy within the context of usual acute care provided was worthwhile in terms of costs for the outcomes gained.
Collapse
Affiliation(s)
- J Kim
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - G Sookram
- Health Economics Unit, Australian Institute of Health and Welfare, Canberra, Australia
| | - E Godecke
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
- Speech Pathology Department, Sir Charles Gairdner Hospital, Perth, Australia
| | - E Brogan
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
- Speech Pathology Department, Sir Charles Gairdner Hospital, Perth, Australia
| | - E Armstrong
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
| | - F Ellery
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - T Rai
- School of Mathematical and Physical Sciences, University of Technology NSW, Broadway, Australia
| | - M L Rose
- School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia
| | - N Ciccone
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
| | - S Middleton
- Nursing Research Institute, Australian Catholic University, Darlinghurst, Australia
| | - A Holland
- University of Arizona, Tucson, AZ, USA
| | - G J Hankey
- Medical School, University of Western Australia, Perth, Australia
- Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia
| | - J Bernhardt
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - D A Cadilhac
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| |
Collapse
|
2
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Kozyrev EA, Kravchenko EA, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Li Y, Lin DX, Middleton S, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Meadows BT, Sokoloff MD, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, De Nardo G, Sciacca C, Jessop CP, LoSecco JM, Honscheid K, Gaz A, Margoni M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Bünger C, Dittrich S, Grünberg O, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Kim P, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Sekula SJ, Ahmed H, Tasneem N, Bellis M, Burchat PR, Puccio EMT, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Miller C, Nugent IM, Roney JM, Sobie RJ, Gershon TJ, Harrison PF, Latham TE, Wu SL. Search for Evidence of Baryogenesis and Dark Matter in B^{+}→ψ_{D}+p Decays at BABAR. Phys Rev Lett 2023; 131:201801. [PMID: 38039482 DOI: 10.1103/physrevlett.131.201801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/12/2023] [Indexed: 12/03/2023]
Abstract
A new dark sector antibaryon, denoted ψ_{D}, could be produced in decays of B mesons. This Letter presents a search for B^{+}→ψ_{D}+p (and the charge conjugate) decays in e^{+}e^{-} annihilations at 10.58 GeV, using data collected in the BABAR experiment. Data corresponding to an integrated luminosity of 398 fb^{-1} are analyzed. No evidence for a signal is observed. Branching fraction upper limits in the range from 10^{-7}-10^{-5} are obtained at 90% confidence level for masses of 1.0
Collapse
|
3
|
Fasugba O, Dale S, McInnes E, Cadilhac DA, Noetel M, Coughlan K, McElduff B, Kim J, Langley T, Cheung NW, Hill K, Pollnow V, Page K, Sanjuan Menendez E, Neal E, Griffith S, Christie LJ, Slark J, Ranta A, Levi C, Grimshaw JM, Middleton S. Evaluating remote facilitation intensity for multi-national translation of nurse-initiated stroke protocols (QASC Australasia): a protocol for a cluster randomised controlled trial. Implement Sci 2023; 18:2. [PMID: 36703172 PMCID: PMC9879239 DOI: 10.1186/s13012-023-01260-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 01/06/2023] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Facilitated implementation of nurse-initiated protocols to manage fever, hyperglycaemia (sugar) and swallowing difficulties (FeSS Protocols) in 19 Australian stroke units resulted in reduced death and dependency for stroke patients. However, a significant gap remains in translating this evidence-based care bundle protocol into standard practice in Australia and New Zealand. Facilitation is a key component for increasing implementation. However, its contribution to evidence translation initiatives requires further investigation. We aim to evaluate two levels of intensity of external remote facilitation as part of a multifaceted intervention to improve FeSS Protocol uptake and quality of care for patients with stroke in Australian and New Zealand acute care hospitals. METHODS A three-arm cluster randomised controlled trial with a process evaluation and economic evaluation. Australian and New Zealand hospitals with a stroke unit or service will be recruited and randomised in blocks of five to one of the three study arms-high- or low-intensity external remote facilitation or a no facilitation control group-in a 2:2:1 ratio. The multicomponent implementation strategy will incorporate implementation science frameworks (Theoretical Domains Framework, Capability, Opportunity, Motivation - Behaviour Model and the Consolidated Framework for Implementation Research) and include an online education package, audit and feedback reports, local clinical champions, barrier and enabler assessments, action plans, reminders and external remote facilitation. The primary outcome is implementation effectiveness using a composite measure comprising six monitoring and treatment elements of the FeSS Protocols. Secondary outcome measures are as follows: composite outcome of adherence to each of the combined monitoring and treatment elements for (i) fever (n=5); (ii) hyperglycaemia (n=6); and (iii) swallowing protocols (n=7); adherence to the individual elements that make up each of these protocols; comparison for composite outcomes between (i) metropolitan and rural/remote hospitals; and (ii) stroke units and stroke services. A process evaluation will examine contextual factors influencing intervention uptake. An economic evaluation will describe cost differences relative to each intervention and study outcomes. DISCUSSION We will generate new evidence on the most effective facilitation intensity to support implementation of nurse-initiated stroke protocols nationwide, reducing geographical barriers for those in rural and remote areas. TRIAL REGISTRATION ACTRN12622000028707. Registered 14 January, 2022.
Collapse
Affiliation(s)
- O Fasugba
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia
| | - S Dale
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia
| | - E McInnes
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia
| | - D A Cadilhac
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
| | - M Noetel
- School of Psychology, University of Queensland, Brisbane, Australia
| | - K Coughlan
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia
| | - B McElduff
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia
| | - J Kim
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
| | - T Langley
- St Vincent's Health Network Sydney, Sydney, New South Wales, Australia
| | - N W Cheung
- Centre for Diabetes and Endocrinology Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia
| | - K Hill
- Stroke Foundation, Sydney, New South Wales, Australia
| | - V Pollnow
- St Vincent's Health Network Sydney, Sydney, New South Wales, Australia
| | - K Page
- St Vincent's Health Network Sydney, Sydney, New South Wales, Australia
| | | | - E Neal
- Prince of Wales Hospital, Randwick, New South Wales, Australia
| | - S Griffith
- School of Psychology, University of Queensland, Brisbane, Australia
| | - L J Christie
- Allied Health Research Unit, St Vincent's Health Network, Sydney, Australia
- School of Allied Health, Faculty of Health Sciences, Australian Catholic University, Sydney, Australia
| | - J Slark
- School of Nursing, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - A Ranta
- Department of Medicine, University of Otago Wellington, Wellington, New Zealand
- Department of Neurology, Wellington Hospital, Wellington, New Zealand
| | - C Levi
- John Hunter Health and Innovation Precinct, New Lambton Heights, New South Wales, Australia
- Department of Medicine, University of Newcastle, Newcastle, New South Wales, Australia
| | - J M Grimshaw
- University of Ottawa, Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - S Middleton
- Nursing Research Institute, St Vincent's Health Network Sydney & St Vincent's Hospital Melbourne & Australian Catholic University, Level 5, deLacy Building, St. Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia.
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia.
| |
Collapse
|
4
|
Robertson A, Makris A, Johnson P, Middleton S, Norman M, Sullivan C, Hennessy A. Delivery outcomes as a result of snoring as determined by standard sleep surveys. Obstet Med 2022; 15:253-259. [PMID: 36523878 PMCID: PMC9745590 DOI: 10.1177/1753495x211064107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Accepted: 11/15/2021] [Indexed: 11/15/2023] Open
Abstract
Background Sleep-disordered breathing (SDB), is an umbrella term that encompasses obstructive sleep apnea (OSA), central sleep apnea (CSA) and hypoventilation. is common but studies in the pregnant population are limited. Data suggests relationships between OSA and preeclampsia, but the relationship between snoring and pregnancy outcomes is unknown. Methods A prospective study of 2224 singleton pregnancies was undertaken. Women were questioned using the Berlin Questionnaire (BQ- 2 or more categories where the score is positive.) and the Epworth Sleepiness Scale (ESS >10/24), the results compared with pregnancy outcomes with regard to hypertension in pregnancy. Results Women having symptoms raising the possibility of OSA defined by the BQ with a score >7 was 45.5%, and using ESS with a score >10, was 36%. The birth and neonatal outcomes for self-reported snoring and increased daytime sleepiness showed increased adverse outcomes notably increased caesarean section rates and low APGAR scores but not birth before 37 weeks of gestation. Conclusion Using questionnaires designed for the general population, the prevalence of possible undiagnosed OSA is high in the pregnant population. The increased adverse delivery and neonatal outcomes for self-reported snoring and increased daytime sleepiness with these tools indicated the need for further investigation of the links between snoring SDB and pregnancy outcomes.
Collapse
Affiliation(s)
- A Robertson
- Western Sydney University
NSW, Australia
- Campbelltown Hospital, South Western Sydney Local Health District, Campbelltown, NSW,
Australia
| | - A Makris
- Liverpool Hospital, Liverpool, NSW, Australia
| | - P Johnson
- David Reid Laboratory, University of Sydney, NSW, Australia
| | - S Middleton
- Liverpool Hospital, Liverpool, NSW, Australia
| | - M Norman
- David Reid Laboratory, University of Sydney, NSW, Australia
| | - C Sullivan
- David Reid Laboratory, University of Sydney, NSW, Australia
| | - A Hennessy
- Western Sydney University
NSW, Australia
- Campbelltown Hospital, South Western Sydney Local Health District, Campbelltown, NSW,
Australia
| |
Collapse
|
5
|
Peiris B, Elmasry M, Middleton S. 543 Bouveret Syndrome: A Rare Presentation of Gastric Outlet Obstruction. Br J Surg 2022. [DOI: 10.1093/bjs/znac269.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Abstract
A 76-year-old lady presented with a 5-day history of lower abdominal pain and vomiting. She had not opened her bowels for 3 days and 24 hours prior to admission had coffee ground vomitus. A CT abdomen and pelvis showed gastric outflow obstruction secondary to a large 3.5cm gallstone within the pylorus (Bouveret syndrome).
She was initially treated conservatively for bowel obstruction and underwent an OGD where attempts to retrieve the stone were unsuccessful. A subsequent laparoscopic gastrotomy revealed a large stone in the duodenum and was successfully removed.
This case highlights how this rare syndrome can present with non-specific symptoms, diagnosis can be challenging and relies on imaging, therefore patients should be worked up thoroughly to ensure a correct diagnosis. There are currently no standardised management guidelines for Bouveret syndrome, mainly due to its rare prevalence and this case demonstrates a variety of management options.
Collapse
Affiliation(s)
- B Peiris
- Royal Berkshire Hospital , Reading , United Kingdom
| | - M Elmasry
- Royal Berkshire Hospital , Reading , United Kingdom
| | - S Middleton
- Royal Berkshire Hospital , Reading , United Kingdom
| |
Collapse
|
6
|
Kouli O, Murray V, Bhatia S, Cambridge WA, Kawka M, Shafi S, Knight SR, Kamarajah SK, McLean KA, Glasbey JC, Khaw RA, Ahmed W, Akhbari M, Baker D, Borakati A, Mills E, Thavayogan R, Yasin I, Raubenheimer K, Ridley W, Sarrami M, Zhang G, Egoroff N, Pockney P, Richards T, Bhangu A, Creagh-Brown B, Edwards M, Harrison EM, Lee M, Nepogodiev D, Pinkney T, Pearse R, Smart N, Vohra R, Sohrabi C, Jamieson A, Nguyen M, Rahman A, English C, Tincknell L, Kakodkar P, Kwek I, Punjabi N, Burns J, Varghese S, Erotocritou M, McGuckin S, Vayalapra S, Dominguez E, Moneim J, Salehi M, Tan HL, Yoong A, Zhu L, Seale B, Nowinka Z, Patel N, Chrisp B, Harris J, Maleyko I, Muneeb F, Gough M, James CE, Skan O, Chowdhury A, Rebuffa N, Khan H, Down B, Fatimah Hussain Q, Adams M, Bailey A, Cullen G, Fu YXJ, McClement B, Taylor A, Aitken S, Bachelet B, Brousse de Gersigny J, Chang C, Khehra B, Lahoud N, Lee Solano M, Louca M, Rozenbroek P, Rozitis E, Agbinya N, Anderson E, Arwi G, Barry I, Batchelor C, Chong T, Choo LY, Clark L, Daniels M, Goh J, Handa A, Hanna J, Huynh L, Jeon A, Kanbour A, Lee A, Lee J, Lee T, Leigh J, Ly D, McGregor F, Moss J, Nejatian M, O'Loughlin E, Ramos I, Sanchez B, Shrivathsa A, Sincari A, Sobhi S, Swart R, Trimboli J, Wignall P, Bourke E, Chong A, Clayton S, Dawson A, Hardy E, Iqbal R, Le L, Mao S, Marinelli I, Metcalfe H, Panicker D, R HH, Ridgway S, Tan HH, Thong S, Van M, Woon S, Woon-Shoo-Tong XS, Yu S, Ali K, Chee J, Chiu C, Chow YW, Duller A, Nagappan P, Ng S, Selvanathan M, Sheridan C, Temple M, Do JE, Dudi-Venkata NN, Humphries E, Li L, Mansour LT, Massy-Westropp C, Fang B, Farbood K, Hong H, Huang Y, Joan M, Koh C, Liu YHA, Mahajan T, Muller E, Park R, Tanudisastro M, Wu JJG, Chopra P, Giang S, Radcliffe S, Thach P, Wallace D, Wilkes A, Chinta SH, Li J, Phan J, Rahman F, Segaran A, Shannon J, Zhang M, Adams N, Bonte A, Choudhry A, Colterjohn N, Croyle JA, Donohue J, Feighery A, Keane A, McNamara D, Munir K, Roche D, Sabnani R, Seligman D, Sharma S, Stickney Z, Suchy H, Tan R, Yordi S, Ahmed I, Aranha M, El Sabawy D, Garwood P, Harnett M, Holohan R, Howard R, Kayyal Y, Krakoski N, Lupo M, McGilberry W, Nepon H, Scoleri Y, Urbina C, Ahmad Fuad MF, Ahmed O, Jaswantlal D, Kelly E, Khan MHT, Naidu D, Neo WX, O'Neill R, Sugrue M, Abbas JD, Abdul-Fattah S, Azlan A, Barry K, Idris NS, Kaka N, Mc Dermott D, Mohammad Nasir MN, Mozo M, Rehal A, Shaikh Yousef M, Wong RH, Curran E, Gardner M, Hogan A, Julka R, Lasser G, Ní Chorráin N, Ting J, Browne R, George S, Janjua Z, Leung Shing V, Megally M, Murphy S, Ravenscroft L, Vedadi A, Vyas V, Bryan A, Sheikh A, Ubhi J, Vannelli K, Vawda A, Adeusi L, Doherty C, Fitzgerald C, Gallagher H, Gill P, Hamza H, Hogan M, Kelly S, Larry J, Lynch P, Mazeni NA, O'Connell R, O'Loghlin R, Singh K, Abbas Syed R, Ali A, Alkandari B, Arnold A, Arora E, Azam R, Breathnach C, Cheema J, Compton M, Curran S, Elliott JA, Jayasamraj O, Mohammed N, Noone A, Pal A, Pandey S, Quinn P, Sheridan R, Siew L, Tan EP, Tio SW, Toh VTR, Walsh M, Yap C, Yassa J, Young T, Agarwal N, Almoosawy SA, Bowen K, Bruce D, Connachan R, Cook A, Daniell A, Elliott M, Fung HKF, Irving A, Laurie S, Lee YJ, Lim ZX, Maddineni S, McClenaghan RE, Muthuganesan V, Ravichandran P, Roberts N, Shaji S, Solt S, Toshney E, Arnold C, Baker O, Belais F, Bojanic C, Byrne M, Chau CYC, De Soysa S, Eldridge M, Fairey M, Fearnhead N, Guéroult A, Ho JSY, Joshi K, Kadiyala N, Khalid S, Khan F, Kumar K, Lewis E, Magee J, Manetta-Jones D, Mann S, McKeown L, Mitrofan C, Mohamed T, Monnickendam A, Ng AYKC, Ortu A, Patel M, Pope T, Pressling S, Purohit K, Saji S, Shah Foridi J, Shah R, Siddiqui SS, Surman K, Utukuri M, Varghese A, Williams CYK, Yang JJ, Billson E, Cheah E, Holmes P, Hussain S, Murdock D, Nicholls A, Patel P, Ramana G, Saleki M, Spence H, Thomas D, Yu C, Abousamra M, Brown C, Conti I, Donnelly A, Durand M, French N, Goan R, O'Kane E, Rubinchik P, Gardiner H, Kempf B, Lai YL, Matthews H, Minford E, Rafferty C, Reid C, Sheridan N, Al Bahri T, Bhoombla N, Rao BM, Titu L, Chatha S, Field C, Gandhi T, Gulati R, Jha R, Jones Sam MT, Karim S, Patel R, Saunders M, Sharma K, Abid S, Heath E, Kurup D, Patel A, Ali M, Cresswell B, Felstead D, Jennings K, Kaluarachchi T, Lazzereschi L, Mayson H, Miah JE, Reinders B, Rosser A, Thomas C, Williams H, Al-Hamid Z, Alsadoun L, Chlubek M, Fernando P, Gaunt E, Gercek Y, Maniar R, Ma R, Matson M, Moore S, Morris A, Nagappan PG, Ratnayake M, Rockall L, Shallcross O, Sinha A, Tan KE, Virdee S, Wenlock R, Donnelly HA, Ghazal R, Hughes I, Liu X, McFadden M, Misbert E, Mogey P, O'Hara A, Peace C, Rainey C, Raja P, Salem M, Salmon J, Tan CH, Alves D, Bahl S, Baker C, Coulthurst J, Koysombat K, Linn T, Rai P, Sharma A, Shergill A, Ahmed M, Ahmed S, Belk LH, Choudhry H, Cummings D, Dixon Y, Dobinson C, Edwards J, Flint J, Franco Da Silva C, Gallie R, Gardener M, Glover T, Greasley M, Hatab A, Howells R, Hussey T, Khan A, Mann A, Morrison H, Ng A, Osmond R, Padmakumar N, Pervaiz F, Prince R, Qureshi A, Sawhney R, Sigurdson B, Stephenson L, Vora K, Zacken A, Cope P, Di Traglia R, Ferarrio I, Hackett N, Healicon R, Horseman L, Lam LI, Meerdink M, Menham D, Murphy R, Nimmo I, Ramaesh A, Rees J, Soame R, Dilaver N, Adebambo D, Brown E, Burt J, Foster K, Kaliyappan L, Knight P, Politis A, Richardson E, Townsend J, Abdi M, Ball M, Easby S, Gill N, Ho E, Iqbal H, Matthews M, Nubi S, Nwokocha JO, Okafor I, Perry G, Sinartio B, Vanukuru N, Walkley D, Welch T, Yates J, Yeshitila N, Bryans K, Campbell B, Gray C, Keys R, Macartney M, Chamberlain G, Khatri A, Kucheria A, Lee STP, Reese G, Roy choudhury J, Tan WYR, Teh JJ, Ting A, Kazi S, Kontovounisios C, Vutipongsatorn K, Amarnath T, Balasubramanian N, Bassett E, Gurung P, Lim J, Panjikkaran A, Sanalla A, Alkoot M, Bacigalupo V, Eardley N, Horton M, Hurry A, Isti C, Maskell P, Nursiah K, Punn G, Salih H, Epanomeritakis E, Foulkes A, Henderson R, Johnston E, McCullough H, McLarnon M, Morrison E, Cheung A, Cho SH, Eriksson F, Hedges J, Low Z, May C, Musto L, Nagi S, Nur S, Salau E, Shabbir S, Thomas MC, Uthayanan L, Vig S, Zaheer M, Zeng G, Ashcroft-Quinn S, Brown R, Hayes J, McConville R, French R, Gilliam A, Sheetal S, Shehzad MU, Bani W, Christie I, Franklyn J, Khan M, Russell J, Smolarek S, Varadarassou R, Ahmed SK, Narayanaswamy S, Sealy J, Shah M, Dodhia V, Manukyan A, O'Hare R, Orbell J, Chung I, Forenc K, Gupta A, Agarwal A, Al Dabbagh A, Bennewith R, Bottomley J, Chu TSM, Chu YYA, Doherty W, Evans B, Hainsworth P, Hosfield T, Li CH, McCullagh I, Mehta A, Thaker A, Thompson B, Virdi A, Walker H, Wilkins E, Dixon C, Hassan MR, Lotca N, Tong KS, Batchelor-Parry H, Chaudhari S, Harris T, Hooper J, Johnson C, Mulvihill C, Nayler J, Olutobi O, Piramanayagam B, Stones K, Sussman M, Weaver C, Alam F, Al Rawi M, Andrew F, Arrayeh A, Azizan N, Hassan A, Iqbal Z, John I, Jones M, Kalake O, Keast M, Nicholas J, Patil A, Powell K, Roberts P, Sabri A, Segue AK, Shah A, Shaik Mohamed SA, Shehadeh A, Shenoy S, Tong A, Upcott M, Vijayasingam D, Anarfi S, Dauncey J, Devindaran A, Havalda P, Komninos G, Mwendwa E, Norman C, Richards J, Urquhart A, Allan J, Cahya E, Hunt H, McWhirter C, Norton R, Roxburgh C, Tan JY, Ali Butt S, Hansdot S, Haq I, Mootien A, Sanchez I, Vainas T, Deliyannis E, Tan M, Vipond M, Chittoor Satish NN, Dattani A, De Carvalho L, Gaston-Grubb M, Karunanithy L, Lowe B, Pace C, Raju K, Roope J, Taylor C, Youssef H, Munro T, Thorn C, Wong KHF, Yunus A, Chawla S, Datta A, Dinesh AA, Field D, Georgi T, Gwozdz A, Hamstead E, Howard N, Isleyen N, Jackson N, Kingdon J, Sagoo KS, Schizas A, Yin L, Aung E, Aung YY, Franklin S, Han SM, Kim WC, Martin Segura A, Rossi M, Ross T, Tirimanna R, Wang B, Zakieh O, Ben-Arzi H, Flach A, Jackson E, Magers S, Olu abara C, Rogers E, Sugden K, Tan H, Veliah S, Walton U, Asif A, Bharwada Y, Bowley D, Broekhuizen A, Cooper L, Evans N, Girdlestone H, Ling C, Mann H, Mehmood N, Mulvenna CL, Rainer N, Trout I, Gujjuri R, Jeyaraman D, Leong E, Singh D, Smith E, Anderton J, Barabas M, Goyal S, Howard D, Joshi A, Mitchell D, Weatherby T, Badminton R, Bird R, Burtle D, Choi NY, Devalia K, Farr E, Fischer F, Fish J, Gunn F, Jacobs D, Johnston P, Kalakoutas A, Lau E, Loo YNAF, Louden H, Makariou N, Mohammadi K, Nayab Y, Ruhomaun S, Ryliskyte R, Saeed M, Shinde P, Sudul M, Theodoropoulou K, Valadao-Spoorenberg J, Vlachou F, Arshad SR, Janmohamed AM, Noor M, Oyerinde O, Saha A, Syed Y, Watkinson W, Ahmadi H, Akintunde A, Alsaady A, Bradley J, Brothwood D, Burton M, Higgs M, Hoyle C, Katsura C, Lathan R, Louani A, Mandalia R, Prihartadi AS, Qaddoura B, Sandland-Taylor L, Thadani S, Thompson A, Walshaw J, Teo S, Ali S, Bawa JH, Fox S, Gargan K, Haider SA, Hanna N, Hatoum A, Khan Z, Krzak AM, Li T, Pitt J, Tan GJS, Ullah Z, Wilson E, Cleaver J, Colman J, Copeland L, Coulson A, Davis P, Faisal H, Hassan F, Hughes JT, Jabr Y, Mahmoud Ali F, Nahaboo Solim ZN, Sangheli A, Shaya S, Thompson R, Cornwall H, De Andres Crespo M, Fay E, Findlay J, Groves E, Jones O, Killen A, Millo J, Thomas S, Ward J, Wilkins M, Zaki F, Zilber E, Bhavra K, Bilolikar A, Charalambous M, Elawad A, Eleni A, Fawdon R, Gibbins A, Livingstone D, Mala D, Oke SE, Padmakumar D, Patsalides MA, Payne D, Ralphs C, Roney A, Sardar N, Stefanova K, Surti F, Timms R, Tosney G, Bannister J, Clement NS, Cullimore V, Kamal F, Lendor J, McKay J, Mcswiggan J, Minhas N, Seneviratne K, Simeen S, Valverde J, Watson N, Bloom I, Dinh TH, Hirniak J, Joseph R, Kansagra M, Lai CKN, Melamed N, Patel J, Randev J, Sedighi T, Shurovi B, Sodhi J, Vadgama N, Abdulla S, Adabavazeh B, Champion A, Chennupati R, Chu K, Devi S, Haji A, Schulz J, Testa F, Davies P, Gurung B, Howell S, Modi P, Pervaiz A, Zahid M, Abdolrazaghi S, Abi Aoun R, Anjum Z, Bawa G, Bhardwaj R, Brown S, Enver M, Gill D, Gopikrishna D, Gurung D, Kanwal A, Kaushal P, Khanna A, Lovell E, McEvoy C, Mirza M, Nabeel S, Naseem S, Pandya K, Perkins R, Pulakal R, Ray M, Reay C, Reilly S, Round A, Seehra J, Shakeel NM, Singh B, Vijay Sukhnani M, Brown L, Desai B, Elzanati H, Godhaniya J, Kavanagh E, Kent J, Kishor A, Liu A, Norwood M, Shaari N, Wood C, Wood M, Brown A, Chellapuri A, Ferriman A, Ghosh I, Kulkarni N, Noton T, Pinto A, Rajesh S, Varghese B, Wenban C, Aly R, Barciela C, Brookes T, Corrin E, Goldsworthy M, Mohamed Azhar MS, Moore J, Nakhuda S, Ng D, Pillay S, Port S, Abdullah M, Akinyemi J, Islam S, Kale A, Lewis A, Manjunath T, McCabe H, Misra S, Stubley T, Tam JP, Waraich N, Chaora T, Ford C, Osinkolu I, Pong G, Rai J, Risquet R, Ainsworth J, Ayandokun P, Barham E, Barrett G, Barry J, Bisson E, Bridges I, Burke D, Cann J, Cloney M, Coates S, Cripps P, Davies C, Francis N, Green S, Handley G, Hathaway D, Hurt L, Jenkins S, Johnston C, Khadka A, McGee U, Morris D, Murray R, Norbury C, Pierrepont Z, Richards C, Ross O, Ruddy A, Salmon C, Shield M, Soanes K, Spencer N, Taverner S, Williams C, Wills-Wood W, Woodward S, Chow J, Fan J, Guest O, Hunter I, Moon WY, Arthur-Quarm S, Edwards P, Hamlyn V, McEneaney L, N D G, Pranoy S, Ting M, Abada S, Alawattegama LH, Ashok A, Carey C, Gogna A, Haglund C, Hurley P, Leelo N, Liu B, Mannan F, Paramjothy K, Ramlogan K, Raymond-Hayling O, Shanmugarajah A, Solichan D, Wilkinson B, Ahmad NA, Allan D, Amin A, Bakina C, Burns F, Cameron F, Campbell A, Cavanagh S, Chan SMZ, Chapman S, Chong V, Edelsten E, Ekpete O, El Sheikh M, Ghose R, Hassane A, Henderson C, Hilton-Christie S, Husain M, Hussain H, Javid Z, Johnson-Ogbuneke J, Johnston A, Khalil M, Leung TCC, Makin I, Muralidharan V, Naeem M, Patil P, Ravichandran S, Saraeva D, Shankey-Smith W, Sharma N, Swan R, Waudby-West R, Wilkinson A, Wright K, Balasubramanian A, Bhatti S, Chalkley M, Chou WK, Dixon M, Evans L, Fisher K, Gandhi P, Ho S, Lau YB, Lowe S, Meechan C, Murali N, Musonda C, Njoku P, Ochieng L, Pervez MU, Seebah K, Shaikh I, Sikder MA, Vanker R, Alom J, Bajaj V, Coleman O, Finch G, Goss J, Jenkins C, Kontothanassis A, Liew MS, Ng K, Outram M, Shakeel MM, Tawn J, Zuhairy S, Chapple K, Cinnamond A, Coleman S, George HA, Goulder L, Hare N, Hawksley J, Kret A, Luesley A, Mecia L, Porter H, Puddy E, Richardson G, Sohail B, Srikaran V, Tadross D, Tobin J, Tokidis E, Young L, Ashdown T, Bratsos S, Koomson A, Kufuor A, Lim MQ, Shah S, Thorne EPC, Warusavitarne J, Xu S, Abigail S, Ahmed A, Ahmed J, Akmal A, Al-Khafaji M, Amini B, Arshad M, Bogie E, Brazkiewicz M, Carroll M, Chandegra A, Cirelli C, Deng A, Fairclough S, Fung YJ, Gornell C, Green RL, Green SV, Gulamhussein AHM, Isaac AG, Jan R, Jegatheeswaran L, Knee M, Kotecha J, Kotecha S, Maxwell-Armstrong C, McIntyre C, Mendis N, Naing TKP, Oberman J, Ong ZX, Ramalingam A, Saeed Adam A, Tan LL, Towell S, Yadav J, Anandampillai R, Chung S, Hounat A, Ibrahim B, Jeyakumar G, Khalil A, Khan UA, Nair G, Owusu-Ayim M, Wilson M, Kanani A, Kilkelly B, Ogunmwonyi I, Ong L, Samra B, Schomerus L, Shea J, Turner O, Yang Y, Amin M, Blott N, Clark A, Feather A, Forrest M, Hague S, Hamilton K, Higginbotham G, Hope E, Karimian S, Loveday K, Malik H, McKenna O, Noor A, Onsiong C, Patel B, Radcliffe N, Shah P, Tye L, Verma K, Walford R, Yusufi U, Zachariah M, Casey A, Doré C, Fludder V, Fortescue L, Kalapu SS, Karel E, Khera G, Smith C, Appleton B, Ashaye A, Boggon E, Evans A, Faris Mahmood H, Hinchcliffe Z, Marei O, Silva I, Spooner C, Thomas G, Timlin M, Wellington J, Yao SL, Abdelrazek M, Abdelrazik Y, Bee F, Joseph A, Mounce A, Parry G, Vignarajah N, Biddles D, Creissen A, Kolhe S, K T, Lea A, Ledda V, O'Loughlin P, Scanlon J, Shetty N, Weller C, Abdalla M, Adeoye A, Bhatti M, Chadda KR, Chu J, Elhakim H, Foster-Davies H, Rabie M, Tailor B, Webb S, Abdelrahim ASA, Choo SY, Jiwa A, Mangam S, Murray S, Shandramohan A, Aghanenu O, Budd W, Hayre J, Khanom S, Liew ZY, McKinney R, Moody N, Muhammad-Kamal H, Odogwu J, Patel D, Roy C, Sattar Z, Shahrokhi N, Sinha I, Thomson E, Wonga L, Bain J, Khan J, Ricardo D, Bevis R, Cherry C, Darkwa S, Drew W, Griffiths E, Konda N, Madani D, Mak JKC, Meda B, Odunukwe U, Preest G, Raheel F, Rajaseharan A, Ramgopal A, Risbrooke C, Selvaratnam K, Sethunath G, Tabassum R, Taylor J, Thakker A, Wijesingha N, Wybrew R, Yasin T, Ahmed Osman A, Alfadhel S, Carberry E, Chen JY, Drake I, Glen P, Jayasuriya N, Kawar L, Myatt R, Sinan LOH, Siu SSY, Tjen V, Adeboyejo O, Bacon H, Barnes R, Birnie C, D'Cunha Kamath A, Hughes E, Middleton S, Owen R, Schofield E, Short C, Smith R, Wang H, Willett M, Zimmerman M, Balfour J, Chadwick T, Coombe-Jones M, Do Le HP, Faulkner G, Hobson K, Shehata Z, Beattie M, Chmielewski G, Chong C, Donnelly B, Drusch B, Ellis J, Farrelly C, Feyi-Waboso J, Hibell I, Hoade L, Ho C, Jones H, Kodiatt B, Lidder P, Ni Cheallaigh L, Norman R, Patabendi I, Penfold H, Playfair M, Pomeroy S, Ralph C, Rottenburg H, Sebastian J, Sheehan M, Stanley V, Welchman J, Ajdarpasic D, Antypas A, Azouaghe O, Basi S, Bettoli G, Bhattarai S, Bommireddy L, Bourne K, Budding J, Cookey-Bresi R, Cummins T, Davies G, Fabelurin C, Gwilliam R, Hanley J, Hird A, Kruczynska A, Langhorne B, Lund J, Lutchman I, McGuinness R, Neary M, Pampapathi S, Pang E, Podbicanin S, Rai N, Redhouse White G, Sujith J, Thomas P, Walker I, Winterton R, Anderson P, Barrington M, Bhadra K, Clark G, Fowler G, Gibson C, Hudson S, Kaminskaite V, Lawday S, Longshaw A, MacKrill E, McLachlan F, Murdeshwar A, Nieuwoudt R, Parker P, Randall R, Rawlins E, Reeves SA, Rye D, Sirkis T, Sykes B, Ventress N, Wosinska N, Akram B, Burton L, Coombs A, Long R, Magowan D, Ong C, Sethi M, Williams G, Chan C, Chan LH, Fernando D, Gaba F, Khor Z, Les JW, Mak R, Moin S, Ng Kee Kwong KC, Paterson-Brown S, Tew YY, Bardon A, Burrell K, Coldwell C, Costa I, Dexter E, Hardy A, Khojani M, Mazurek J, Raymond T, Reddy V, Reynolds J, Soma A, Agiotakis S, Alsusa H, Desai N, Peristerakis I, Adcock A, Ayub H, Bennett T, Bibi F, Brenac S, Chapman T, Clarke G, Clark F, Galvin C, Gwyn-Jones A, Henry-Blake C, Kerner S, Kiandee M, Lovett A, Pilecka A, Ravindran R, Siddique H, Sikand T, Treadwell K, Akmal K, Apata A, Barton O, Broad G, Darling H, Dhuga Y, Emms L, Habib S, Jain R, Jeater J, Kan CYP, Kathiravelupillai A, Khatkar H, Kirmani S, Kulasabanathan K, Lacey H, Lal K, Manafa C, Mansoor M, McDonald S, Mittal A, Mustoe S, Nottrodt L, Oliver P, Papapetrou I, Pattinson F, Raja M, Reyhani H, Shahmiri A, Small O, Soni U, Aguirrezabala Armbruster B, Bunni J, Hakim MA, Hawkins-Hooker L, Howell KA, Hullait R, Jaskowska A, Ottewell L, Thomas-Jones I, Vasudev A, Clements B, Fenton J, Gill M, Haider S, Lim AJM, Maguire H, McMullan J, Nicoletti J, Samuel S, Unais MA, White N, Yao PC, Yow L, Boyle C, Brady R, Cheekoty P, Cheong J, Chew SJHL, Chow R, Ganewatta Kankanamge D, Mamer L, Mohammed B, Ng Chieng Hin J, Renji Chungath R, Royston A, Sharrad E, Sinclair R, Tingle S, Treherne K, Wyatt F, Maniarasu VS, Moug S, Appanna T, Bucknall T, Hussain F, Owen A, Parry M, Parry R, Sagua N, Spofforth K, Yuen ECT, Bosley N, Hardie W, Moore T, Regas C, Abdel-Khaleq S, Ali N, Bashiti H, Buxton-Hopley R, Constantinides M, D'Afflitto M, Deshpande A, Duque Golding J, Frisira E, Germani Batacchi M, Gomaa A, Hay D, Hutchison R, Iakovou A, Iakovou D, Ismail E, Jefferson S, Jones L, Khouli Y, Knowles C, Mason J, McCaughan R, Moffatt J, Morawala A, Nadir H, Neyroud F, Nikookam Y, Parmar A, Pinto L, Ramamoorthy R, Richards E, Thomson S, Trainer C, Valetopoulou A, Vassiliou A, Wantman A, Wilde S, Dickinson M, Rockall T, Senn D, Wcislo K, Zalmay P, Adelekan K, Allen K, Bajaj M, Gatumbu P, Hang S, Hashmi Y, Kaur T, Kawesha A, Kisiel A, Woodmass M, Adelowo T, Ahari D, Alhwaishel K, Atherton R, Clayton B, Cockroft A, Curtis Lopez C, Hilton M, Ismail N, Kouadria M, Lee L, MacConnachie A, Monks F, Mungroo S, Nikoletopoulou C, Pearce L, Sara X, Shahid A, Suresh G, Wilcha R, Atiyah A, Davies E, Dermanis A, Gibbons H, Hyde A, Lawson A, Lee C, Leung-Tack M, Li Saw Hee J, Mostafa O, Nair D, Pattani N, Plumbley-Jones J, Pufal K, Ramesh P, Sanghera J, Saram S, Scadding S, See S, Stringer H, Torrance A, Vardon H, Wyn-Griffiths F, Brew A, Kaur G, Soni D, Tickle A, Akbar Z, Appleyard T, Figg K, Jayawardena P, Johnson A, Kamran Siddiqui Z, Lacy-Colson J, Oatham R, Rowlands B, Sludden E, Turnbull C, Allin D, Ansar Z, Azeez Z, Dale VH, Garg J, Horner A, Jones S, Knight S, McGregor C, McKenna J, McLelland T, Packham-Smith A, Rowsell K, Spector-Hill I, Adeniken E, Baker J, Bartlett M, Chikomba L, Connell B, Deekonda P, Dhar M, Elmansouri A, Gamage K, Goodhew R, Hanna P, Knight J, Luca A, Maasoumi N, Mahamoud F, Manji S, Marwaha PK, Mason F, Oluboyede A, Pigott L, Razaq AM, Richardson M, Saddaoui I, Wijeyendram P, Yau S, Atkins W, Liang K, Miles N, Praveen B, Ashai S, Braganza J, Common J, Cundy A, Davies R, Guthrie J, Handa I, Iqbal M, Ismail R, Jones C, Jones I, Lee KS, Levene A, Okocha M, Olivier J, Smith A, Subramaniam E, Tandle S, Wang A, Watson A, Wilson C, Chan XHF, Khoo E, Montgomery C, Norris M, Pugalenthi PP, Common T, Cook E, Mistry H, Shinmar HS, Agarwal G, Bandyopadhyay S, Brazier B, Carroll L, Goede A, Harbourne A, Lakhani A, Lami M, Larwood J, Martin J, Merchant J, Pattenden S, Pradhan A, Raafat N, Rothwell E, Shammoon Y, Sudarshan R, Vickers E, Wingfield L, Ashworth I, Azizi S, Bhate R, Chowdhury T, Christou A, Davies L, Dwaraknath M, Farah Y, Garner J, Gureviciute E, Hart E, Jain A, Javid S, Kankam HK, Kaur Toor P, Kaz R, Kermali M, Khan I, Mattson A, McManus A, Murphy M, Nair K, Ngemoh D, Norton E, Olabiran A, Parry L, Payne T, Pillai K, Price S, Punjabi K, Raghunathan A, Ramwell A, Raza M, Ritehnia J, Simpson G, Smith W, Sodeinde S, Studd L, Subramaniam M, Thomas J, Towey S, Tsang E, Tuteja D, Vasani J, Vio M, Badran A, Adams J, Anthony Wilkinson J, Asvandi S, Austin T, Bald A, Bix E, Carrick M, Chander B, Chowdhury S, Cooper Drake B, Crosbie S, D Portela S, Francis D, Gallagher C, Gillespie R, Gravett H, Gupta P, Ilyas C, James G, Johny J, Jones A, Kinder F, MacLeod C, Macrow C, Maqsood-Shah A, Mather J, McCann L, McMahon R, Mitham E, Mohamed M, Munton E, Nightingale K, O'Neill K, Onyemuchara I, Senior R, Shanahan A, Sherlock J, Spyridoulias A, Stavrou C, Stokes D, Tamang R, Taylor E, Trafford C, Uden C, Waddington C, Yassin D, Zaman M, Bangi S, Cheng T, Chew D, Hussain N, Imani-Masouleh S, Mahasivam G, McKnight G, Ng HL, Ota HC, Pasha T, Ravindran W, Shah K, Vishnu K S, Zaman S, Carr W, Cope S, Eagles EJ, Howarth-Maddison M, Li CY, Reed J, Ridge A, Stubbs T, Teasdaled D, Umar R, Worthington J, Dhebri A, Kalenderov R, Alattas A, Arain Z, Bhudia R, Chia D, Daniel S, Dar T, Garland H, Girish M, Hampson A, Kyriacou H, Lehovsky K, Mullins W, Omorphos N, Vasdev N, Venkatesh A, Waldock W, Bhandari A, Brown G, Choa G, Eichenauer CE, Ezennia K, Kidwai Z, Lloyd-Thomas A, Macaskill Stewart A, Massardi C, Sinclair E, Skajaa N, Smith M, Tan I, Afsheen N, Anuar A, Azam Z, Bhatia P, Davies-kelly N, Dickinson S, Elkawafi M, Ganapathy M, Gupta S, Khoury EG, Licudi D, Mehta V, Neequaye S, Nita G, Tay VL, Zhao S, Botsa E, Cuthbert H, Elliott J, Furlepa M, Lehmann J, Mangtani A, Narayan A, Nazarian S, Parmar C, Shah D, Shaw C, Zhao Z, Beck C, Caldwell S, Clements JM, French B, Kenny R, Kirk S, Lindsay J, McClung A, McLaughlin N, Watson S, Whiteside E, Alyacoubi S, Arumugam V, Beg R, Dawas K, Garg S, Lloyd ER, Mahfouz Y, Manobharath N, Moonesinghe R, Morka N, Patel K, Prashar J, Yip S, Adeeko ES, Ajekigbe F, Bhat A, Evans C, Farrugia A, Gurung C, Long T, Malik B, Manirajan S, Newport D, Rayer J, Ridha A, Ross E, Saran T, Sinker A, Waruingi D, Allen R, Al Sadek Y, Alves do Canto Brum H, Asharaf H, Ashman M, Balakumar V, Barrington J, Baskaran R, Berry A, Bhachoo H, Bilal A, Boaden L, Chia WL, Covell G, Crook D, Dadnam F, Davis L, De Berker H, Doyle C, Fox C, Gruffydd-Davies M, Hafouda Y, Hill A, Hubbard E, Hunter A, Inpadhas V, Jamshaid M, Jandu G, Jeyanthi M, Jones T, Kantor C, Kwak SY, Malik N, Matt R, McNulty P, Miles C, Mohomed A, Myat P, Niharika J, Nixon A, O'Reilly D, Parmar K, Pengelly S, Price L, Ramsden M, Turnor R, Wales E, Waring H, Wu M, Yang T, Ye TTS, Zander A, Zeicu C, Bellam S, Francombe J, Kawamoto N, Rahman MR, Sathyanarayana A, Tang HT, Cheung J, Hollingshead J, Page V, Sugarman J, Wong E, Chiong J, Fung E, Kan SY, Kiang J, Kok J, Krahelski O, Liew MY, Lyell B, Sharif Z, Speake D, Alim L, Amakye NY, Chandrasekaran J, Chandratreya N, Drake J, Owoso T, Thu YM, Abou El Ela Bourquin B, Alberts J, Chapman D, Rehnnuma N, Ainsworth K, Carpenter H, Emmanuel T, Fisher T, Gabrel M, Guan Z, Hollows S, Hotouras A, Ip Fung Chun N, Jaffer S, Kallikas G, Kennedy N, Lewinsohn B, Liu FY, Mohammed S, Rutherfurd A, Situ T, Stammer A, Taylor F, Thin N, Urgesi E, Zhang N, Ahmad MA, Bishop A, Bowes A, Dixit A, Glasson R, Hatta S, Hatt K, Larcombe S, Preece J, Riordan E, Fegredo D, Haq MZ, Li C, McCann G, Stewart D, Baraza W, Bhullar D, Burt G, Coyle J, Deans J, Devine A, Hird R, Ikotun O, Manchip G, Ross C, Storey L, Tan WWL, Tse C, Warner C, Whitehead M, Wu F, Court EL, Crisp E, Huttman M, Mayes F, Robertson H, Rosen H, Sandberg C, Smith H, Al Bakry M, Ashwell W, Bajaj S, Bandyopadhyay D, Browlee O, Burway S, Chand CP, Elsayeh K, Elsharkawi A, Evans E, Ferrin S, Fort-Schaale A, Iacob M, I K, Impelliziere Licastro G, Mankoo AS, Olaniyan T, Otun J, Pereira R, Reddy R, Saeed D, Simmonds O, Singhal G, Tron K, Wickstone C, Williams R, Bradshaw E, De Kock Jewell V, Houlden C, Knight C, Metezai H, Mirza-Davies A, Seymour Z, Spink D, Wischhusen S. Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study. Lancet Digit Health 2022; 4:e520-e531. [PMID: 35750401 DOI: 10.1016/s2589-7500(22)00069-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Revised: 01/07/2022] [Accepted: 04/06/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Stratifying risk of postoperative pulmonary complications after major abdominal surgery allows clinicians to modify risk through targeted interventions and enhanced monitoring. In this study, we aimed to identify and validate prognostic models against a new consensus definition of postoperative pulmonary complications. METHODS We did a systematic review and international external validation cohort study. The systematic review was done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched MEDLINE and Embase on March 1, 2020, for articles published in English that reported on risk prediction models for postoperative pulmonary complications following abdominal surgery. External validation of existing models was done within a prospective international cohort study of adult patients (≥18 years) undergoing major abdominal surgery. Data were collected between Jan 1, 2019, and April 30, 2019, in the UK, Ireland, and Australia. Discriminative ability and prognostic accuracy summary statistics were compared between models for the 30-day postoperative pulmonary complication rate as defined by the Standardised Endpoints in Perioperative Medicine Core Outcome Measures in Perioperative and Anaesthetic Care (StEP-COMPAC). Model performance was compared using the area under the receiver operating characteristic curve (AUROCC). FINDINGS In total, we identified 2903 records from our literature search; of which, 2514 (86·6%) unique records were screened, 121 (4·8%) of 2514 full texts were assessed for eligibility, and 29 unique prognostic models were identified. Nine (31·0%) of 29 models had score development reported only, 19 (65·5%) had undergone internal validation, and only four (13·8%) had been externally validated. Data to validate six eligible models were collected in the international external validation cohort study. Data from 11 591 patients were available, with an overall postoperative pulmonary complication rate of 7·8% (n=903). None of the six models showed good discrimination (defined as AUROCC ≥0·70) for identifying postoperative pulmonary complications, with the Assess Respiratory Risk in Surgical Patients in Catalonia score showing the best discrimination (AUROCC 0·700 [95% CI 0·683-0·717]). INTERPRETATION In the pre-COVID-19 pandemic data, variability in the risk of pulmonary complications (StEP-COMPAC definition) following major abdominal surgery was poorly described by existing prognostication tools. To improve surgical safety during the COVID-19 pandemic recovery and beyond, novel risk stratification tools are required. FUNDING British Journal of Surgery Society.
Collapse
|
7
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Golubev VB, Kozyrev EA, Kravchenko EA, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Kim J, Li Y, Lin DX, Middleton S, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Huard Z, Meadows BT, Pushpawela BG, Sokoloff MD, Sun L, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Flood I, Nguyen N, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Gabathuler E, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, Taras P, De Nardo G, Sciacca C, Raven G, Jessop CP, LoSecco JM, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, De Nuccio M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dorfan J, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Innes WR, Kim P, Leith DWGS, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Randle-Conde A, Sekula SJ, Ahmed H, Tasneem N, Bellis M, Burchat PR, Puccio EMT, Alam MS, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Schwitters RF, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Miller C, Nugent IM, Roney JM, Sobie RJ, Gershon TJ, Harrison PF, Latham TE, Prepost R, Wu SL. Search for an Axionlike Particle in B Meson Decays. Phys Rev Lett 2022; 128:131802. [PMID: 35426701 DOI: 10.1103/physrevlett.128.131802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 01/31/2022] [Accepted: 03/07/2022] [Indexed: 06/14/2023]
Abstract
Axionlike particles (ALPs) are predicted in many extensions of the standard model, and their masses can naturally be well below the electroweak scale. In the presence of couplings to electroweak bosons, these particles could be emitted in flavor-changing B meson decays. We report herein a search for an ALP, a, in the reaction B^{±}→K^{±}a, a→γγ using data collected by the BABAR experiment at SLAC. No significant signal is observed, and 90% confidence level upper limits on the ALP coupling to electroweak bosons are derived as a function of ALP mass, improving current constraints by several orders of magnitude in the range 0.175 GeV<m_{a}<4.78 GeV.
Collapse
Affiliation(s)
- J P Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Tisserand
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - E Grauges
- Universitat de Barcelona, Facultat de Fisica, Departament ECM, E-08028 Barcelona, Spain
| | - A Palano
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - G Eigen
- University of Bergen, Institute of Physics, N-5007 Bergen, Norway
| | - D N Brown
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - Yu G Kolomensky
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - M Fritsch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - H Koch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - T Schroeder
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - C Hearty
- Institute of Particle Physics, Vancouver, British Columbia, Canada V6T 1Z1
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - T S Mattison
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - R Y So
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - V E Blinov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - A R Buzykaev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
| | - V P Druzhinin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - V B Golubev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kozyrev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kravchenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A P Onuchin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - S I Serednyakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - Yu I Skovpen
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E P Solodov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - K Yu Todyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A J Lankford
- University of California at Irvine, Irvine, California 92697, USA
| | - B Dey
- University of California at Riverside, Riverside, California 92521, USA
| | - J W Gary
- University of California at Riverside, Riverside, California 92521, USA
| | - O Long
- University of California at Riverside, Riverside, California 92521, USA
| | - A M Eisner
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W S Lockman
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W Panduro Vazquez
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - D S Chao
- California Institute of Technology, Pasadena, California 91125, USA
| | - C H Cheng
- California Institute of Technology, Pasadena, California 91125, USA
| | - B Echenard
- California Institute of Technology, Pasadena, California 91125, USA
| | - K T Flood
- California Institute of Technology, Pasadena, California 91125, USA
| | - D G Hitlin
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Kim
- California Institute of Technology, Pasadena, California 91125, USA
| | - Y Li
- California Institute of Technology, Pasadena, California 91125, USA
| | - D X Lin
- California Institute of Technology, Pasadena, California 91125, USA
| | - S Middleton
- California Institute of Technology, Pasadena, California 91125, USA
| | - T S Miyashita
- California Institute of Technology, Pasadena, California 91125, USA
| | - P Ongmongkolkul
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Oyang
- California Institute of Technology, Pasadena, California 91125, USA
| | - F C Porter
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Röhrken
- California Institute of Technology, Pasadena, California 91125, USA
| | - Z Huard
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B T Meadows
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | | | - M D Sokoloff
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Sun
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J G Smith
- University of Colorado, Boulder, Colorado 80309, USA
| | - S R Wagner
- University of Colorado, Boulder, Colorado 80309, USA
| | - D Bernard
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - M Verderi
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - D Bettoni
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - C Bozzi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Calabrese
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - G Cibinetto
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - E Fioravanti
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - I Garzia
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - E Luppi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - V Santoro
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Martellotti
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - I M Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Rotondo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - A Zallo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Passaggio
- INFN Sezione di Genova, I-16146 Genova, Italy
| | | | - I Flood
- Harvey Mudd College, Claremont, California 91711, USA
| | - N Nguyen
- Harvey Mudd College, Claremont, California 91711, USA
| | - B J Shuve
- Harvey Mudd College, Claremont, California 91711, USA
| | - H M Lacker
- Humboldt-Universität zu Berlin, Institut für Physik, D-12489 Berlin, Germany
| | - B Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, Assam, 781 039, India
| | - U Mallik
- University of Iowa, Iowa City, Iowa 52242, USA
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - J Cochran
- Iowa State University, Ames, Iowa 50011, USA
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - A V Gritsan
- Johns Hopkins University, Baltimore, Maryland 21218, USA
| | - N Arnaud
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - M Davier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - F Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - A M Lutz
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - G Wormser
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - D J Lange
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D M Wright
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J P Coleman
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gabathuler
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D E Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D J Payne
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - C Touramanis
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - A J Bevan
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - F Di Lodovico
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - R Sacco
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - G Cowan
- University of London, Royal Holloway and Bedford New College, Egham, Surrey TW20 0EX, United Kingdom
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - D N Brown
- University of Louisville, Louisville, Kentucky 40292, USA
| | - C L Davis
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A G Denig
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K Griessinger
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - A Hafner
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K R Schubert
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - R J Barlow
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - G D Lafferty
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - R Cenci
- University of Maryland, College Park, Maryland 20742, USA
| | - A Jawahery
- University of Maryland, College Park, Maryland 20742, USA
| | - D A Roberts
- University of Maryland, College Park, Maryland 20742, USA
| | - R Cowan
- Massachusetts Institute of Technology, Laboratory for Nuclear Science, Cambridge, Massachusetts 02139, USA
| | - S H Robertson
- Institute of Particle Physics, Montréal, Québec, Canada H3A 2T8
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - R M Seddon
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - N Neri
- INFN Sezione di Milano, I-20133 Milano, Italy
| | - F Palombo
- INFN Sezione di Milano, I-20133 Milano, Italy
- Dipartimento di Fisica, Università di Milano, I-20133 Milano, Italy
| | - L Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - R Godang
- University of Mississippi, University, Mississippi 38677, USA
| | - D J Summers
- University of Mississippi, University, Mississippi 38677, USA
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec, Canada H3C 3J7
| | - G De Nardo
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - C Sciacca
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G Raven
- NIKHEF, National Institute for Nuclear Physics and High Energy Physics, NL-1009 DB Amsterdam, The Netherlands
| | - C P Jessop
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - J M LoSecco
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - K Honscheid
- Ohio State University, Columbus, Ohio 43210, USA
| | - R Kass
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Margoni
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - M Posocco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - G Simi
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - F Simonetto
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - S Akar
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - E Ben-Haim
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Bomben
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G R Bonneaud
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Calderini
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Chauveau
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Marchiori
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Ocariz
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Biasini
- INFN Sezione di Perugia, I-06123 Perugia, Italy
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - A Rossi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - G Batignani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Carpinelli
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | | | - M De Nuccio
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M A Giorgi
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A Lusiani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Scuola Normale Superiore di Pisa, I-56127 Pisa, Italy
| | - B Oberhof
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Rama
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - J J Walsh
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A J S Smith
- Princeton University, Princeton, New Jersey 08544, USA
| | - F Anulli
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - R Faccini
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | | | - F Ferroni
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - A Pilloni
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | - G Piredda
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - C Bünger
- Universität Rostock, D-18051 Rostock, Germany
| | - S Dittrich
- Universität Rostock, D-18051 Rostock, Germany
| | - O Grünberg
- Universität Rostock, D-18051 Rostock, Germany
| | - M Heß
- Universität Rostock, D-18051 Rostock, Germany
| | - T Leddig
- Universität Rostock, D-18051 Rostock, Germany
| | - C Voß
- Universität Rostock, D-18051 Rostock, Germany
| | - R Waldi
- Universität Rostock, D-18051 Rostock, Germany
| | - T Adye
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - F F Wilson
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - S Emery
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Vasseur
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D Aston
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Cartaro
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M R Convery
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Dorfan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W Dunwoodie
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M Ebert
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - R C Field
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B G Fulsom
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M T Graham
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Hast
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W R Innes
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - P Kim
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D W G S Leith
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D R Muller
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - H Neal
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - A Roodman
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M K Sullivan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Va'vra
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M V Purohit
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - J R Wilson
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - S J Sekula
- Southern Methodist University, Dallas, Texas 75275, USA
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia, Canada B2G 2W5
| | - N Tasneem
- St. Francis Xavier University, Antigonish, Nova Scotia, Canada B2G 2W5
| | - M Bellis
- Stanford University, Stanford, California 94305, USA
| | - P R Burchat
- Stanford University, Stanford, California 94305, USA
| | - E M T Puccio
- Stanford University, Stanford, California 94305, USA
| | - M S Alam
- State University of New York, Albany, New York 12222, USA
| | - J A Ernst
- State University of New York, Albany, New York 12222, USA
| | - R Gorodeisky
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - N Guttman
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - D R Peimer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - S M Spanier
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J L Ritchie
- University of Texas at Austin, Austin, Texas 78712, USA
| | | | - J M Izen
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - X C Lou
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - F De Mori
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - A Filippi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - D Gamba
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - L Lanceri
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - L Vitale
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | | | - A Oyanguren
- IFIC, Universitat de Valencia-CSIC, E-46071 Valencia, Spain
| | - J Albert
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - A Beaulieu
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - F U Bernlochner
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - G J King
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - T Lueck
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - C Miller
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - I M Nugent
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - J M Roney
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - R J Sobie
- Institute of Particle Physics, Victoria, British Columbia, Canada V8W 3P6
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - T J Gershon
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P F Harrison
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - T E Latham
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - R Prepost
- University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S L Wu
- University of Wisconsin, Madison, Wisconsin 53706, USA
| |
Collapse
|
8
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Golubev VB, Kozyrev EA, Kravchenko EA, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Kim J, Li Y, Lin DX, Middleton S, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Huard Z, Meadows BT, Pushpawela BG, Sokoloff MD, Sun L, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Gabathuler E, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, Taras P, De Nardo G, Sciacca C, Raven G, Jessop CP, LoSecco JM, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dorfan J, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Innes WR, Kim P, Leith DWGS, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Randle-Conde A, Sekula SJ, Ahmed H, Bellis M, Burchat PR, Puccio EMT, Alam MS, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Schwitters RF, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Nugent IM, Roney JM, Sobie RJ, Tasneem N, Gershon TJ, Harrison PF, Latham TE, Prepost R, Wu SL. Search for Lepton Flavor Violation in ϒ(3S)→e^{±}μ^{∓}. Phys Rev Lett 2022; 128:091804. [PMID: 35302790 DOI: 10.1103/physrevlett.128.091804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 01/27/2022] [Indexed: 06/14/2023]
Abstract
We report on the first search for electron-muon lepton flavor violation (LFV) in the decay of a b quark and b antiquark bound state. We look for the LFV decay ϒ(3S)→e^{±}μ^{∓} in a sample of 118 million ϒ(3S) mesons from 27 fb^{-1} of data collected with the BABAR detector at the SLAC PEP-II e^{+}e^{-} collider operating with a 10.36 GeV center-of-mass energy. No evidence for a signal is found, and we set a limit on the branching fraction B[ϒ(3S)→e^{±}μ^{∓}]<3.6×10^{-7} at 90% C. L. This result can be interpreted as a limit Λ_{NP}/g_{NP}^{2}>80 TeV on the energy scale Λ_{NP} divided by the coupling-squared g_{NP}^{2} of relevant new physics (NP).
Collapse
Affiliation(s)
- J P Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Tisserand
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - E Grauges
- Universitat de Barcelona, Facultat de Fisica, Departament ECM, E-08028 Barcelona, Spain
| | - A Palano
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - G Eigen
- University of Bergen, Institute of Physics, N-5007 Bergen, Norway
| | - D N Brown
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - Yu G Kolomensky
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - M Fritsch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - H Koch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - T Schroeder
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - C Hearty
- Institute of Particle Physics, Vancouver, British Columbia V6T 1Z1, Canada
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - T S Mattison
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - R Y So
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - V E Blinov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - A R Buzykaev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
| | - V P Druzhinin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - V B Golubev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kozyrev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kravchenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A P Onuchin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - S I Serednyakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - Yu I Skovpen
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E P Solodov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - K Yu Todyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A J Lankford
- University of California at Irvine, Irvine, California 92697, USA
| | - B Dey
- University of California at Riverside, Riverside, California 92521, USA
| | - J W Gary
- University of California at Riverside, Riverside, California 92521, USA
| | - O Long
- University of California at Riverside, Riverside, California 92521, USA
| | - A M Eisner
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W S Lockman
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W Panduro Vazquez
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - D S Chao
- California Institute of Technology, Pasadena, California 91125, USA
| | - C H Cheng
- California Institute of Technology, Pasadena, California 91125, USA
| | - B Echenard
- California Institute of Technology, Pasadena, California 91125, USA
| | - K T Flood
- California Institute of Technology, Pasadena, California 91125, USA
| | - D G Hitlin
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Kim
- California Institute of Technology, Pasadena, California 91125, USA
| | - Y Li
- California Institute of Technology, Pasadena, California 91125, USA
| | - D X Lin
- California Institute of Technology, Pasadena, California 91125, USA
| | - S Middleton
- California Institute of Technology, Pasadena, California 91125, USA
| | - T S Miyashita
- California Institute of Technology, Pasadena, California 91125, USA
| | - P Ongmongkolkul
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Oyang
- California Institute of Technology, Pasadena, California 91125, USA
| | - F C Porter
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Röhrken
- California Institute of Technology, Pasadena, California 91125, USA
| | - Z Huard
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B T Meadows
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | | | - M D Sokoloff
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Sun
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J G Smith
- University of Colorado, Boulder, Colorado 80309, USA
| | - S R Wagner
- University of Colorado, Boulder, Colorado 80309, USA
| | - D Bernard
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - M Verderi
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - D Bettoni
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - C Bozzi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Calabrese
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - G Cibinetto
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Fioravanti
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - I Garzia
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Luppi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - V Santoro
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Martellotti
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - I M Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Rotondo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - A Zallo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Passaggio
- INFN Sezione di Genova, I-16146 Genova, Italy
| | | | - B J Shuve
- Harvey Mudd College, Claremont, California 91711, USA
| | - H M Lacker
- Humboldt-Universität zu Berlin, Institut für Physik, D-12489 Berlin, Germany
| | - B Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, Assam 781 039, India
| | - U Mallik
- University of Iowa, Iowa City, Iowa 52242, USA
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - J Cochran
- Iowa State University, Ames, Iowa 50011, USA
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - A V Gritsan
- Johns Hopkins University, Baltimore, Maryland 21218, USA
| | - N Arnaud
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - M Davier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - F Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - A M Lutz
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - G Wormser
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - D J Lange
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D M Wright
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J P Coleman
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gabathuler
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D E Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D J Payne
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - C Touramanis
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - A J Bevan
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - F Di Lodovico
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - R Sacco
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - G Cowan
- University of London, Royal Holloway and Bedford New College, Egham, Surrey TW20 0EX, United Kingdom
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - D N Brown
- University of Louisville, Louisville, Kentucky 40292, USA
| | - C L Davis
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A G Denig
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K Griessinger
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - A Hafner
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K R Schubert
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - R J Barlow
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - G D Lafferty
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - R Cenci
- University of Maryland, College Park, Maryland 20742, USA
| | - A Jawahery
- University of Maryland, College Park, Maryland 20742, USA
| | - D A Roberts
- University of Maryland, College Park, Maryland 20742, USA
| | - R Cowan
- Massachusetts Institute of Technology, Laboratory for Nuclear Science, Cambridge, Massachusetts 02139, USA
| | - S H Robertson
- Institute of Particle Physics, Montréal, Québec H3A 2T8, Canada
- McGill University, Montréal, Québec H3A 2T8, Canada
| | - R M Seddon
- Institute of Particle Physics, Montréal, Québec H3A 2T8, Canada
| | - N Neri
- INFN Sezione di Milano, I-20133 Milano, Italy
| | - F Palombo
- INFN Sezione di Milano, I-20133 Milano, Italy
- Dipartimento di Fisica, Università di Milano, I-20133 Milano, Italy
| | - L Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - R Godang
- University of Mississippi, University, Mississippi 38677, USA
| | - D J Summers
- University of Mississippi, University, Mississippi 38677, USA
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec H3C 3J7, Canada
| | - G De Nardo
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - C Sciacca
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G Raven
- NIKHEF, National Institute for Nuclear Physics and High Energy Physics, NL-1009 DB Amsterdam, Netherlands
| | - C P Jessop
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - J M LoSecco
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - K Honscheid
- Ohio State University, Columbus, Ohio 43210, USA
| | - R Kass
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Margoni
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - M Posocco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - G Simi
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - F Simonetto
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - S Akar
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - E Ben-Haim
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Bomben
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G R Bonneaud
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Calderini
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Chauveau
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Marchiori
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Ocariz
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Biasini
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - A Rossi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - G Batignani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Carpinelli
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | | | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M A Giorgi
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A Lusiani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Scuola Normale Superiore di Pisa, I-56127 Pisa, Italy
| | - B Oberhof
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Rama
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - J J Walsh
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A J S Smith
- Princeton University, Princeton, New Jersey 08544, USA
| | - F Anulli
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - R Faccini
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | | | - F Ferroni
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - A Pilloni
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | - G Piredda
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - C Bünger
- Universität Rostock, D-18051 Rostock, Germany
| | - S Dittrich
- Universität Rostock, D-18051 Rostock, Germany
| | - O Grünberg
- Universität Rostock, D-18051 Rostock, Germany
| | - M Heß
- Universität Rostock, D-18051 Rostock, Germany
| | - T Leddig
- Universität Rostock, D-18051 Rostock, Germany
| | - C Voß
- Universität Rostock, D-18051 Rostock, Germany
| | - R Waldi
- Universität Rostock, D-18051 Rostock, Germany
| | - T Adye
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - F F Wilson
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - S Emery
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Vasseur
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D Aston
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - C Cartaro
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M R Convery
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - J Dorfan
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W Dunwoodie
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M Ebert
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - R C Field
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - B G Fulsom
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M T Graham
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - C Hast
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W R Innes
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - P Kim
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D W G S Leith
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D R Muller
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - H Neal
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - A Roodman
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M K Sullivan
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - J Va'vra
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M V Purohit
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - J R Wilson
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - S J Sekula
- Southern Methodist University, Dallas, Texas 75275, USA
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia B2G 2W5, Canada
| | - M Bellis
- Stanford University, Stanford, California 94305, USA
| | - P R Burchat
- Stanford University, Stanford, California 94305, USA
| | - E M T Puccio
- Stanford University, Stanford, California 94305, USA
| | - M S Alam
- State University of New York, Albany, New York 12222, USA
| | - J A Ernst
- State University of New York, Albany, New York 12222, USA
| | - R Gorodeisky
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - N Guttman
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - D R Peimer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - S M Spanier
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J L Ritchie
- University of Texas at Austin, Austin, Texas 78712, USA
| | | | - J M Izen
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - X C Lou
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - F De Mori
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - A Filippi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - D Gamba
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - L Lanceri
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - L Vitale
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | | | - A Oyanguren
- IFIC, Universitat de Valencia-CSIC, E-46071 Valencia, Spain
| | - J Albert
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - A Beaulieu
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - F U Bernlochner
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - G J King
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T Lueck
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - I M Nugent
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - J M Roney
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R J Sobie
- Institute of Particle Physics, Victoria, British Columbia V8W 3P6, Canada
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - N Tasneem
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T J Gershon
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P F Harrison
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - T E Latham
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - R Prepost
- University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S L Wu
- University of Wisconsin, Madison, Wisconsin 53706, USA
| |
Collapse
|
9
|
Fasugba O, McInnes E, Baye J, Cheng H, Gordon R, Middleton S. Barriers and enablers to implementinghospital-acquired urinary tract infection prevention strategies: a qualitative study using the Theoretical Domains Framework. J Hosp Infect 2021; 113:172-179. [PMID: 33839213 DOI: 10.1016/j.jhin.2021.03.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/30/2021] [Accepted: 03/31/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Consistent implementation of evidence-based hospital-acquired urinary tract infection (UTI) prevention strategies remains a challenge in acute and subacute care settings. Addressing the evidence-practice gap requires an understanding of factors affecting implementation of hospital-acquired UTI prevention strategies in this high-risk setting. AIM To identify the perceived barriers and enablers of clinicians to implementing hospital-acquired UTI prevention strategies in an Australian subacute hospital. METHODS Qualitative semi-structured virtual interviews, underpinned by the Theoretical Domains Framework (TDF), were conducted with purposively selected nurses (N = 8) and doctors (N = 2) at one subacute metropolitan hospital. Interview data were content-analysed using the TDF as the coding framework. FINDINGS Eight TDF domains were identified as important in understanding barriers and enablers to implementing hospital-acquired UTI prevention strategies: Knowledge, Skills, Beliefs about capabilities, Emotion, Professional role and identity, Environmental context and resources, Goals, and Behavioural regulation. Barriers were poor awareness of clinical practice guidelines for hospital-acquired UTI prevention; lack of training; staff shortages; competing workloads; lack of procedural equipment for urinary catheterization; difficulty with implementing prevention strategies in cognitively impaired patients; language barriers; and lack of feedback and use of incident reporting data to influence clinical practice. Presence of a proactive staff culture and positive team approach to work emerged as enablers. Audit and feedback, clinical champions, education, and patient information resources in languages other than English were identified as potential enablers. CONCLUSION The findings will inform development of theoretically informed behaviour change interventions to promote successful implementation of hospital-acquired UTI prevention strategies in the subacute setting.
Collapse
Affiliation(s)
- O Fasugba
- Nursing Research Institute, St Vincent's Health Network Sydney, St Vincent's Hospital Melbourne & Australian Catholic University, Darlinghurst, New South Wales, Australia.
| | - E McInnes
- Nursing Research Institute, St Vincent's Health Network Sydney, St Vincent's Hospital Melbourne & Australian Catholic University, Darlinghurst, New South Wales, Australia
| | - J Baye
- St Joseph's Hospital, Auburn, New South Wales, Australia
| | - H Cheng
- Nursing Research Institute, St Vincent's Health Network Sydney, St Vincent's Hospital Melbourne & Australian Catholic University, Darlinghurst, New South Wales, Australia
| | - R Gordon
- St Joseph's Hospital, Auburn, New South Wales, Australia
| | - S Middleton
- Nursing Research Institute, St Vincent's Health Network Sydney, St Vincent's Hospital Melbourne & Australian Catholic University, Darlinghurst, New South Wales, Australia
| |
Collapse
|
10
|
Jaarsma T, Strömberg A, Dunbar SB, Fitzsimons D, Lee C, Middleton S, Vellone E, Freedland KE, Riegel B. Self-care research: How to grow the evidence base? (reprint). Int J Nurs Stud 2021; 116:103903. [PMID: 33637295 DOI: 10.1016/j.ijnurstu.2021.103903] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 02/18/2020] [Accepted: 02/26/2020] [Indexed: 01/03/2023]
Abstract
BACKGROUND AND OBJECTIVE The number of studies in the area of self-care is growing and international researchers are increasingly developing self-care interventions to improve outcomes of individual patients and communities. However, growth of the evidence is still slow due to challenges with designing and testing self-care interventions. In this article we address major methodological challenges with regard to the definition of self-care, use of theory, and research design, intended to provide guidance to researchers in this field. METHOD During the inaugural conference of the International Center for Self-Care Research held in Rome, Italy in June 2019 we identified important issues in existing self-care research. Discussion and literature review lead to eight recommendation for future self-care research. RESULTS In preparation, begin with a theoretically sound definition of self-care. In planning the intervention, build on and extend previous studies. Use theory to develop self-care interventions and consider translational models to guide development, evaluation and implementation of complex self-care interventions. Employ a study design that fits the current phase and objectives of the research and measure self-care and related factors carefully. In reporting, describe the sample and setting sufficiently so that others can draw conclusions about generalizability and applicability to their practice and patient population. In interpretation, describe how the intervention is assumed to work (causal assumptions) and its key components. CONCLUSION Our review of existing self-care research clearly illustrates that the recommendations we provide are needed if we are to substantially grow the evidence base supporting self-care. Embracing a core set of principles will allow us to build on each other's work. Tweetable abstract: A core set of methodological principles is needed to substantially grow the evidence base supporting self-care.
Collapse
Affiliation(s)
- T Jaarsma
- Department of Health, Medicine and Caring Sciences, Linkoping University, 58381 Linköping, Sweden; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; Julius Center, University Medical Center Utrecht, the Netherlands.
| | - A Strömberg
- Department of Health, Medicine and Caring Sciences, Linkoping University, 58381 Linköping, Sweden; Department of Cardiology, Linkoping University, Sweden
| | - S B Dunbar
- Nell Hodgson Woodruff School of Nursing, Emory University, USA
| | - D Fitzsimons
- School of Nursing & Midwifery, Queen's University Belfast, UK
| | - C Lee
- William F. Connell, School of Nursing, Boston College, USA
| | - S Middleton
- Nursing Research Institute, St Vincent's Health Australia & Australian Catholic University, Australia
| | - E Vellone
- University of Rome "Tor Vergata", Italy
| | - K E Freedland
- Department of Psychiatry, Washington University School of Medicine, USA
| | - B Riegel
- Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; School of Nursing, University of Pennsylvania, USA
| |
Collapse
|
11
|
Middleton S, Pfeilschifter W. International translation of Fever, Sugar, Swallow Protocols: The Quality in Acute Stroke Care Europe Project. Int J Stroke 2020; 15:591-594. [DOI: 10.1177/1747493020915130] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The Quality in Acute Stroke (QASC) trial demonstrated a significant reduction in death and disability when clinicians were assisted to introduce protocols to manage fever, hyperglycaemia (sugar) and swallowing (FeSS) following stroke. We describe a unique international collaboration between the Nursing Research Institute at Australian Catholic University; the European Stroke Organisation; and the Angels Initiative, working collaboratively to support implementation of the nurse-led FeSS Protocols in 20 European countries. We currently have 71 hospitals from 16 countries participating (hospitals from four countries are in the preparation phase) with 49 hospitals currently entering data (n=2819 patients to-date). Baseline data have been received from 39 hospitals, with FeSS Protocol implementation commenced at 16 hospitals. Five hospitals have completed the Project. 'Upscale and spread' of these evidence-based, nursing protocols into countries with vastly different healthcare systems, many of whom also have no access to the latest stroke therapies, is likely to make a significant impact in reducing death and disability after stroke.
Collapse
Affiliation(s)
- S Middleton
- St Vincent's Health Australia Sydney, St Vincent's Hospital, Melbourne and Australian Catholic University, NSW, Australia
| | - W Pfeilschifter
- Department of Neurology, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
12
|
Fasugba O, Mitchell BG, McInnes E, Koerner J, Cheng AC, Cheng H, Middleton S. Increased fluid intake for the prevention of urinary tract infection in adults and children in all settings: a systematic review. J Hosp Infect 2019; 104:68-77. [PMID: 31449918 DOI: 10.1016/j.jhin.2019.08.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 08/19/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND Non-antibiotic interventions for urinary tract infection (UTI) prevention have been investigated as a strategy to reduce antibiotic prescribing for UTI and subsequent antibiotic resistance. Increased hydration is widely advocated for preventing UTI; however, evidence for its effectiveness is unknown. AIM To systematically review the published literature on the effectiveness of increased fluid intake as a preventive intervention for UTI in adults and children in any setting. METHODS Five electronic databases were searched from inception to February 2019 to identify published randomized controlled trials (RCTs) and quasi-experimental studies evaluating the effectiveness of high (≥1.5 L/24 h) versus normal/low (<1.5 L/24 h) fluid intake for UTI prevention. The outcome was UTI incidence. Risk of bias was assessed using the Cochrane Collaboration's tool. Due to the small number of studies identified, meta-analysis was not possible. Hence a narrative synthesis was undertaken. FINDINGS Of the 2822 potentially relevant papers, two were eligible for inclusion: an RCT (individual randomization) and a cluster-RCT. Both studies differed regarding participants, setting, sample size, UTI definition, and intervention. The RCT was assessed as having a low risk of bias whereas the cluster-RCT had a high risk of bias. Only the RCT, which included healthy premenopausal women visiting primary care clinics, demonstrated statistical significance for the effect of high fluid intake for UTI prevention. CONCLUSION The lack of enough adequately powered and robust RCTs highlights the need for further research on the effectiveness of this intervention for UTI prevention.
Collapse
Affiliation(s)
- O Fasugba
- Nursing Research Institute, St Vincent's Health Australia Sydney, St Vincent's Hospital, Melbourne & Australian Catholic University, Australia; Lifestyle Research Centre, Avondale College of Higher Education, Cooranbong, New South Wales, Australia.
| | - B G Mitchell
- Faculty of Arts, Nursing, and Theology, Avondale College of Higher Education, Wahroonga, New South Wales, Australia; School of Nursing and Midwifery, University of Newcastle, Newcastle, New South Wales, Australia
| | - E McInnes
- Nursing Research Institute, St Vincent's Health Australia Sydney, St Vincent's Hospital, Melbourne & Australian Catholic University, Australia
| | - J Koerner
- School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Canberra, Australian Capital Territory, Australia
| | - A C Cheng
- Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
| | - H Cheng
- Nursing Research Institute, St Vincent's Health Australia Sydney, St Vincent's Hospital, Melbourne & Australian Catholic University, Australia
| | - S Middleton
- Nursing Research Institute, St Vincent's Health Australia Sydney, St Vincent's Hospital, Melbourne & Australian Catholic University, Australia
| |
Collapse
|
13
|
Leggett G, Butler A, Massey D, Middleton S, Russell N, Woodward J, Green J, Bond D, Duncan S, Woolner L, Sharkey L. A summary of 10 years of transplant activity and outcomes from a UK centre for intestinal and multivisceral transplantation. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.2063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Herting F, Friess T, Umaña P, Middleton S, Klein C. Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. Leuk Lymphoma 2017; 59:1482-1485. [DOI: 10.1080/10428194.2017.1376740] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Frank Herting
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany
| | - Thomas Friess
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany
| | - Pablo Umaña
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
| | - Steven Middleton
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, USA
| | - Christian Klein
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
| |
Collapse
|
15
|
Bradley B, Middleton S, Davis N, Williams M, Stocker M, Hockings M, Isaac DL. Discharge on the day of surgery following unicompartmental knee arthroplasty within the United Kingdom NHS. Bone Joint J 2017; 99-B:788-792. [PMID: 28566398 DOI: 10.1302/0301-620x.99b6.bjj-2016-0540.r2] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 01/27/2017] [Indexed: 11/05/2022]
Abstract
AIMS Unicompartmental knee arthroplasty (UKA) has been successfully performed in the United States healthcare system on outpatients. Despite differences in healthcare structure and financial environment, we hypothesised that it would be feasible to replicate this success and perform UKA with safe day of surgery discharge within the NHS, in the United Kingdom. This has not been reported in any other United Kingdom centres. PATIENTS AND METHODS We report our experience of implementing a pathway to allow safe day of surgery discharge following UKA. Data were prospectively collected on 72 patients who underwent UKA as a day case between December 2011 and September 2015. RESULTS A total of 61 patients (85%) were discharged on the same day. The most common reason for failure was logistical; five patients had their operation too late in the day. Three patients failed to mobilise safely, two had inadequate control of pain and one had a leaking wound. The mean length of stay for those who were not discharged on the same day was 1.2 nights (1 to 3). During the same time, 58 patients underwent planned inpatient UKA, as they were deemed inappropriate for discharge on the day of surgery. However, three of these were safely discharged on the same day. Follow-up data, 24 hours post-operatively, were available for 70 patients; 51 (73%) reported no or mild pain, 14 (20%) had moderate pain and five (7%) had severe pain. There were no re-admissions. All patients had a high level of satisfaction. CONCLUSION We found that patients can be safely and effectively discharged on the day of surgery after UKA, with high levels of satisfaction. This clearly offers improved management of resources and financial savings to healthcare trusts. Cite this article: Bone Joint J 2017;99-B:788-92.
Collapse
Affiliation(s)
- B Bradley
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - S Middleton
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - N Davis
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Williams
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Stocker
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Hockings
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - D L Isaac
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| |
Collapse
|
16
|
Middleton S, Walker RW, Norton M. Decortication and osteotomy for the correction of multiplanar deformity in the treatment of malunion in adult diaphyseal femoral deformity: a case series and technique description. Eur J Orthop Surg Traumatol 2017; 28:117-120. [PMID: 28660434 DOI: 10.1007/s00590-017-2008-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 06/21/2017] [Indexed: 10/19/2022]
Abstract
AIM To review patients that have undergone correction of a symptomatic femoral malunion using osteotomy combined with decortication. METHODS A retrospective review of all patients who have undergone decortication and multiplanar osteotomy, looking at the pre-operative deformity, correction achieved, time to union and complications. RESULTS Seven patients underwent correction under the senior author from 2003 to 2012. Average age was 46 years (range 32-60 years). All had femoral shortening deformity (average 2.7 cm, range 2-4 cm). Each also had at least one other plane of deformity with rotation being the next most commonly encountered in 5 out of the 7 (average 33°, range 0°-45°). Two had tri-planar deformity with the five having bi-planar deformity. Average time to union was 16.3 months (range 7-39 months) with an average of 1.5 operations (range 1-3 operations) to union. One patient has a non-union after five corrective operations. CONCLUSION Correction of multiplanar deformity of the femur is challenging. Osteotomy with decortication provides a technique to achieve significant femoral multiplanar deformity correction in a single operation. This publication provides technical description of the operative technique, guidance and results.
Collapse
Affiliation(s)
- S Middleton
- Department of Trauma and Orthopaedics, Royal Cornwall Hospital, Penventinnie Lane, Truro, Cornwall, TR1 3LJ, UK
| | - R W Walker
- Department of Trauma and Orthopaedics, Royal Cornwall Hospital, Penventinnie Lane, Truro, Cornwall, TR1 3LJ, UK.
| | - M Norton
- Department of Trauma and Orthopaedics, Royal Cornwall Hospital, Penventinnie Lane, Truro, Cornwall, TR1 3LJ, UK
| |
Collapse
|
17
|
Ambrose T, Sharkey LM, Louis-Auguste J, Rutter CS, Duncan S, English S, Gkrania-Klotsas E, Carmichael A, Woodward JM, Russell N, Massey D, Butler A, Middleton S. Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation. Transplant Proc 2017; 48:492-6. [PMID: 27109985 DOI: 10.1016/j.transproceed.2015.09.070] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Accepted: 09/03/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Cytomegalovirus (CMV) disease is a common and clinically significant complication following intestinal or multivisceral transplantation. CMV disease is more common in cases of serologic mismatch between donor and recipient. Though in some cases it may be asymptomatic, in the immunosuppressed population it often manifests with evidence of systemic infection or end-organ disease. METHODS We conducted a retrospective review of all patients undergoing intestinal or multivisceral transplantation over 8 years at our institution. RESULTS Forty-eight transplantations were performed, with 40% of the patients (19/48) having ≥1 episode of CMV viremia, which rose to 90% in the "donor-positive, recipient-negative" (DPRN) serologic mismatch group. The median time to 1st episode following transplantation was 22.3 weeks (range, 1-78) and median duration of each episode was 4.9 weeks (range, 1.6-37.4). Six of the 19 viremic patients (31.6%) developed virologic resistance with 4 of these occurring in the DPRN group. Four of the 6 patients with drug-resistant CMV died with CMV viremia. All patients with drug resistance acquired ganciclovir resistance; these patients were more challenging to manage with second-line toxicity-limited treatments, including foscarnet, cidofovir, and leflunomide. CMV immunoglobulin has been used and we briefly discuss the use of CMV-specific adoptive T-lymphocyte transfer in the management of 1 case. CONCLUSIONS Post-transplantation CMV disease continues to be challenging to manage, and there is little consensus on optimal management strategies in this patient group, with a significant requirement for novel therapies; these may be pharmacologic or cell based. Extensive multidisciplinary discussion is important for most cases, but particularly for those patients who acquire virologic resistance.
Collapse
Affiliation(s)
- T Ambrose
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - L M Sharkey
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - J Louis-Auguste
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - C S Rutter
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Duncan
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S English
- Department of Clinical Virology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - E Gkrania-Klotsas
- Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - A Carmichael
- Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - J M Woodward
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - N Russell
- Department of Transplant Surgery, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - D Massey
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - A Butler
- Department of Transplant Surgery, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Middleton
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, United Kingdom.
| |
Collapse
|
18
|
Razak A, Gore L, Britten C, Miller W, Uy G, Nichols G, Middleton S, Blotner S, Zhi J, Jukofsky L, Pierceall W, Higgins B, Chen L. A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32645-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Abstract
We explored the literature surrounding whether allergy and hypersensitivity has a clinical basis for implant selection in total knee arthroplasty (TKA). In error, the terms hypersensitivity and allergy are often used synonymously. Although a relationship is present, we could not find any evidence of implant failure due to allergy. There is however increasing basic science that suggests a link between loosening and metal ion production. This is not an allergic response but is a potential problem. With a lack of evidence logically there can be no justification to use 'hypoallergenic' implants in patients who have pre-existing skin sensitivity to the metals used in TKA.
Collapse
Affiliation(s)
- S Middleton
- Royal Devon and Exeter Hospitals Foundation Trust, Barrack Rd, Exeter, EX2 5DW, UK
| | - A Toms
- Royal Devon and Exeter Hospitals Foundation Trust, Barrack Rd, Exeter, EX2 5DW, UK
| |
Collapse
|
20
|
Sturgeon J, Middleton S, Rico T, Mackey S, Johnson K. (161) Differential daily effects of pain intensity, sleep, and mood on physical activity in chronic back pain. The Journal of Pain 2016. [DOI: 10.1016/j.jpain.2016.01.064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Rost NS, Bottle A, Lee JM, Randall M, Middleton S, Shaw L, Thijs V, Rinkel GJE, Hemmen TM. Stroke Severity Is a Crucial Predictor of Outcome: An International Prospective Validation Study. J Am Heart Assoc 2016; 5:JAHA.115.002433. [PMID: 26796252 PMCID: PMC4859362 DOI: 10.1161/jaha.115.002433] [Citation(s) in RCA: 132] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background Stroke is among the leading causes of morbidity and mortality worldwide. Without reliable prediction models and outcome measurements, comparison of care systems is impossible. We analyzed prospectively collected data from 4 countries to explore the importance of stroke severity in outcome prediction. Methods and Results For 2 months, all acute ischemic stroke patients from the hospitals participating in the Global Comparators Stroke GOAL (Global Outcomes Accelerated Learning) collaboration received a National Institutes of Health Stroke Scale (NIHSS) score on admission and a modified Rankin Scale score at 30 and 90 days. These data were added to the administrative data set, and risk prediction models including age, sex, comorbidity index, and NIHSS were derived for in‐hospital death within 7 days, all in‐hospital death, and death and good outcome at 30 and 90 days. The relative importance of each variable was assessed using the proportion of explained variation. Of 1034 admissions for acute ischemic stroke, 614 had a full set of NIHSS and both modified Rankin Scale values recorded; of these, 507 patients could be linked to administrative data. The marginal proportion of explained variation was 0.7% to 4.0% for comorbidity index, and 11.3 to 25.0 for NIHSS score. The percentage explained by the model varied by outcome (16.6–29.1%) and was highest for good outcome at 30 and 90 days. There was high agreement between 30‐ and 90‐day modified Rankin Scale scores (weighted κ=0.82). Conclusions In this prospective pilot study, the baseline NIHSS score was essential for prediction of acute ischemic stroke outcomes, followed by age; whereas traditional comorbidity index contributed little to the overall model. Future studies of stroke outcomes between different care systems will benefit from including a baseline NIHSS score.
Collapse
Affiliation(s)
- Natalia S Rost
- Stroke Division, Neurology Department, Massachusetts General Hospital, Boston, MA (N.S.R.)
| | - Alex Bottle
- Dr. Foster Unit at Imperial College London, London, UK (A.B.)
| | - Jin-Moo Lee
- Stroke Center, Department of Neurology and the Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO (J.M.L.)
| | - Marc Randall
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK (M.R.)
| | | | - Louise Shaw
- Royal United Hospital Bath NHS Trust, Bath, UK (L.S.)
| | - Vincent Thijs
- University Hospitals Leuven, Department of Neurology, Leuven, Belgium (V.T.) Austin Health and Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia (V.T.)
| | - Gabriel J E Rinkel
- Department of Neurology & Neurosurgery, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands (G.E.R.)
| | - Thomas M Hemmen
- University of California - San Diego Health System, San Diego, CA (T.M.H.)
| | | |
Collapse
|
22
|
Higgins B, Tovar C, Glen K, Railkar A, Filipovic Z, Qureshi F, Vu B, Ehrlich G, Fishlock D, Chen LC, Middleton S, Nichols G, Packman K, Vassilev L. Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-a156] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The p53 tumor suppressor is a transcription factor that inhibits tumorigenesis by inducing cell cycle arrest or apoptosis in response to diverse stresses. In normal cells, p53 levels are tightly controlled by MDM2 which binds p53 and negatively regulates its activity and stability. MDM2 is overproduced in many human cancers, thereby impairing p53 function. Antagonists of p53-MDM2 interaction can enhance p53 activity and offer a novel approach to cancer therapy. The first potent and selective small-molecule inhibitors of p53-MDM2 binding, the nutlins, provided preclinical proof-of-concept for MDM2 antagonists as therapeutics for patients with tumors expressing wild-type p53. The nutlin family member idasanutlin (RG7388, RO5503781) is an oral small molecule inhibitor of MDM2 currently in clinical testing.
Here we describe RO6839921, a pegylated prodrug formulated for intravenous administration. This IV MDM2 antagonist has been developed in order to improve variability in exposure seen with the oral compound, and to allow expansion into indications where patients cannot swallow or absorb the oral idasanutlin. RO6839921 is rapidly metabolized to the active principle (AP) idasanutlin which then binds selectively to the p53 site on the surface of the MDM2 molecule. In vitro testing with the AP shows high affinity with effective displacement of p53 from MDM2, leading to stabilization and accumulation of p53 protein and activation of the p53 pathway. Studies focused on in vivo investigation of activity of the prodrug RO6839921 since esterase cleavage is required to release the AP. The anti-tumor activity of RO6839921 was investigated in several sarcoma xenograft models including highly responsive wild-type (WT) p53, MDM2 overexpressing osteosarcoma models SJSA-1 and MHM. Sustained survival was seen in the WT p53 HT1080 fibrosarcoma model when combined with Doxil. Activity was also seen in the WT p53 MOLM-13 disseminated AML model alone and in combination with cytarabine, in the CRPC model 22rv1, and in the ER+ BCa model MCF-7.
In these studies we see an increase in dose commensurate with exposure and activity (prodrug vs oral), less variability, and potentiated activity in combination with relevant therapeutics.
Clinical studies with the oral AP (idasanutlin) have shown that p53 may be activated by this novel therapeutic strategy that releases p53 from MDM2 inhibition. In particular, patients with AML exhibit significant clinical activity (ASH 2014). In view of the existing unmet medical need in advanced cancers, and the promising activity seen with idasanutlin, RO6839921 is believed to be a promising agent that may offer new therapeutic options, and is therefore currently in clinical testing in both solid and hematologic malignancies.
Citation Format: Brian Higgins, Christian Tovar, Kelli Glen, Aruna Railkar, Zoran Filipovic, Farooq Qureshi, Binh Vu, George Ehrlich, Dan Fishlock, Lin-Chi Chen, Steven Middleton, Gwen Nichols, Kathryn Packman, Lyubomir Vassilev. Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156.
Collapse
Affiliation(s)
- Brian Higgins
- 1Pharma Research and Early Development; Roche Innovation Center New York, New York, NY
| | | | | | | | | | | | - Binh Vu
- 2Roche Research Center, Nutley, NJ
| | | | - Dan Fishlock
- 3Pharma Research and Early Development; Roche Innovation Center Basel, Basel, Switzerland
| | - Lin-Chi Chen
- 1Pharma Research and Early Development; Roche Innovation Center New York, New York, NY
| | - Steven Middleton
- 1Pharma Research and Early Development; Roche Innovation Center New York, New York, NY
| | - Gwen Nichols
- 1Pharma Research and Early Development; Roche Innovation Center New York, New York, NY
| | | | | |
Collapse
|
23
|
Gao R, Kratzing C, Pither C, Sharkey L, West S, Butler A, Woodward J, Duncan S, Green J, Chukualim B, Gabe S, Jamieson N, Middleton S. Nutritional outcomes following small bowel transplantation – The first year post-operative nutritional nadir. Clin Nutr ESPEN 2015; 10:e190-e191. [DOI: 10.1016/j.clnesp.2015.03.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Munoz Venturelli P, Olavarría V, Brunser A, Lavados P, Pontes O, Arima H, Hackett M, Lim J, Middleton S, Watkins C, Robinson T, Peng B, Cui L, Lee H, Lin R, Anderson C. Head position in stroke trial (Headpost): an international cluster randomized trial. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.1407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Phelps DA, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, Middleton S, Wang D, Mo X, Houghton PJ. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer 2015; 62:1345-52. [PMID: 25832557 PMCID: PMC4563820 DOI: 10.1002/pbc.25465] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 01/19/2015] [Indexed: 11/05/2022]
Abstract
BACKGROUND Curative therapy for childhood sarcoma presents challenges when complete resection is not possible. Ionizing radiation (XRT) is used as a standard modality at diagnosis or recurrence for childhood sarcoma; however, local recurrence is still problematic. Most childhood sarcomas are TP53 wild type at diagnosis, although approximately 5-10% have MDM2 amplification or overexpression. PROCEDURES The MDM2 inhibitor, RG7388, was examined alone or in combination with XRT (20Gy given in 2 Gy daily fractions) to immune-deficient mice bearing Rh18 (embryonal) or a total of 30 Gy in 2 Gy fractions to mice bearing Rh30 (alveolar) rhabdomyosarcoma xenografts. RG7388 was administered by oral gavage using two schedules (daily ×5; schedule 1 or once weekly; schedule 2). TP53-responsive gene products (p21, PUMA, DDB2, and MIC1) as well as markers of apoptosis were analyzed. RESULTS RG7388 showed no significant single agent antitumor activity. Twenty Grays XRT induced complete regressions (CR) of Rh18 with 100 percent tumor regrowth by week 7, but no tumor regrowth at 20 weeks when combined with RG7388. RG7388 enhanced time to recurrence combined with XRT in Rh30 xenografts compared to 30 Gy XRT alone. RG7388 did not enhance XRT-induced local skin toxicity. Combination treatments induced TP53 responsive genes more rapidly and to a greater magnitude than single agent treatments. CONCLUSIONS RG7388 enhanced the activity of XRT in both rhabdomyosarcoma models without increasing local XRT-induced skin toxicity. Changes in TP53-responsive genes were consistent with the synergistic activity of RG7388 and XRT in the Rh18 model.
Collapse
Affiliation(s)
- Doris A. Phelps
- Center for Childhood Cancer & Blood Diseases, Nationwide Children’s Hospital, Columbus, OH 43205
| | - Kathryn Bondra
- Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute
| | - Star Seum
- Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute
| | - Christopher Chronowski
- Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute
| | - Justin Leasure
- Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute
| | - Raushan T. Kurmasheva
- Center for Childhood Cancer & Blood Diseases, Nationwide Children’s Hospital, Columbus, OH 43205
| | | | - Dian Wang
- Department of Radiation Oncology, Rush University Medical Center Chicago, IL
| | - Xiaokui Mo
- Center for Biostatistics, The Ohio State University
| | - Peter J. Houghton
- Center for Childhood Cancer & Blood Diseases, Nationwide Children’s Hospital, Columbus, OH 43205
| |
Collapse
|
26
|
Munasinghe A, Chang D, Mamidanna R, Middleton S, Joy M, Penninckx F, Darzi A, Livingston E, Faiz O. Reconciliation of international administrative coding systems for comparison of colorectal surgery outcome. Colorectal Dis 2014; 16:555-61. [PMID: 24661398 DOI: 10.1111/codi.12624] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 02/15/2014] [Indexed: 02/08/2023]
Abstract
AIM Significant variation in colorectal surgery outcomes exists between different countries. Better understanding of the sources of variable outcomes using administrative data requires alignment of differing clinical coding systems. We aimed to map similar diagnoses and procedures across administrative coding systems used in different countries. METHOD Administrative data were collected in a central database as part of the Global Comparators (GC) Project. In order to unify these data, a systematic translation of diagnostic and procedural codes was undertaken. Codes for colorectal diagnoses, resections, operative complications and reoperative interventions were mapped across the respective national healthcare administrative coding systems. Discharge data from January 2006 to June 2011 for patients who had undergone colorectal surgical resections were analysed to generate risk-adjusted models for mortality, length of stay, readmissions and reoperations. RESULTS In all, 52 544 case records were collated from 31 institutions in five countries. Mapping of all the coding systems was achieved so that diagnosis and procedures from the participant countries could be compared. Using the aligned coding systems to develop risk-adjusted models, the 30-day mortality rate for colorectal surgery was 3.95% (95% CI 0.86-7.54), the 30-day readmission rate was 11.05% (5.67-17.61), the 28-day reoperation rate was 6.13% (3.68-9.66) and the mean length of stay was 14 (7.65-46.76) days. CONCLUSION The linkage of international hospital administrative data that we developed enabled comparison of documented surgical outcomes between countries. This methodology may facilitate international benchmarking.
Collapse
Affiliation(s)
- A Munasinghe
- Department of Surgery and Cancer, Imperial College, St Mary's Hospital, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Siu LL, Italiano A, Miller WH, Blay JY, Gietema JA, Bang YJ, Mileshkin LR, Hirte HW, Reckner M, Higgins B, Jukofsky L, Blotner S, Zhi J, Middleton S, Nichols GL, Chen LC. Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.2535] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Wilson H. Miller
- Segal Cancer Center, Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada
| | | | - Jourik A. Gietema
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Yung-Jue Bang
- Department of Internal Medicine and Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | | | | | - Monica Reckner
- Hoffmann-La Roche, Translational and Clinical Research Center, New York, NY
| | - Brian Higgins
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY
| | - Lori Jukofsky
- Hoffmann-La Roche, Translational Clinical Research Center, Oncology Translational Medicine, New York, NY
| | - Steven Blotner
- Hoffmann-La Roche Inc., Translational Clinical Research Center, New York, NY
| | - Jianguo Zhi
- Hoffmann-La Roche Inc., Translational Clinical Research Center, New York, NY
| | - Steven Middleton
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY
| | - Gwen L. Nichols
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY
| | - Lin Chi Chen
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY
| |
Collapse
|
28
|
Marang-van de Mheen PJ, Lingsma HF, Middleton S, Kievit J, Steyerberg EW. EVALUATION OF QUALITY OF CARE USING REGISTRY DATA: THE INTERRELATIONSHIP BETWEEN LENGTH-OF-STAY, READMISSION AND MORTALITY AND IMPACT ON HOSPITAL OUTCOMES. BMJ Qual Saf 2014. [DOI: 10.1136/bmjqs-2014-002893.9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Walker R, Middleton S, Stapley SA. The principles of managing open fractures. J R Nav Med Serv 2014; 100:18-23. [PMID: 24881422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Any fracture of a bone which communicates with the outside environment via a wound in the skin is classified as an open fracture. This may be from penetration by sharp objects from the exterior, laceration caused by the fracture fragments, or shearing forces that tear or de-glove soft tissue from a limb. These injuries vary in mechanism and severity, ranging from a broken finger caught in a bulkhead door to a catastrophic lower limb fracture suffered from an improvised explosive device (IED). We address the management principles that can be applied to all open fractures regardless of cause.
Collapse
|
30
|
Abstract
Since the introduction of ventral mesh rectopexy for rectal prolapse, concern exists as to how this may interfere with subsequent rectal cancer surgery. To our knowledge, this is the first report of total mesorectal excision for cancer after such a rectopexy. We discuss surgical technique, pitfalls encountered and oncological outcome.
Collapse
Affiliation(s)
- S S Antonowicz
- Royal Berkshire Hospital, London Road, Reading RG1 5AN, UK.
| | | | | |
Collapse
|
31
|
Bottle A, Middleton S, Kalkman CJ, Livingston EH, Aylin P. Global comparators project: international comparison of hospital outcomes using administrative data. Health Serv Res 2013; 48:2081-100. [PMID: 23742025 DOI: 10.1111/1475-6773.12074] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE To produce comparable risk-adjusted outcome rates for an international sample of hospitals in a collaborative project to share outcomes and learning. DATA SOURCES Administrative data varying in scope, format, and coding systems were pooled from each participating hospital for the years 2005-2010. STUDY DESIGN Following reconciliation of the different coding systems in the various countries, in-hospital mortality, unplanned readmission within 30 days, and "prolonged" hospital stay (>75th percentile) were risk-adjusted via logistic regression. A web-based interface was created to facilitate outcomes analysis for individual medical centers and enable peer comparisons. Small groups of clinicians are now exploring the potential reasons for variations in outcomes in their specialty. PRINCIPAL FINDINGS There were 6,737,211 inpatient records, including 214,622 in-hospital deaths. Although diagnostic coding depth varied appreciably by country, comorbidity weights were broadly comparable. U.S. hospitals generally had the lowest mortality rates, shortest stays, and highest readmission rates. CONCLUSIONS Intercountry differences in outcomes may result from differences in the quality of care or in practice patterns driven by socio-economic factors. Carefully managed administrative data can be an effective resource for initiating dialog between hospitals within and across countries. Inclusion of important outcomes beyond hospital discharge would increase the value of these analyses.
Collapse
Affiliation(s)
- Alex Bottle
- Dr. Foster Unit at Imperial College London, Department of Primary Care and Public Health, School of Public Health, London, UK
| | | | | | | | | |
Collapse
|
32
|
Chawla SP, Blay JY, Italiano A, Gutierrez M, Le Cesne A, Gomez-Roca CA, Gouw LG, von Mehren M, Wagner A, Maki RG, Higgins B, Middleton S, Nichols GL, Geho D, Blotner S, Zhi J, Chen LC. Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.10514] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10514 Background: Preclinical data demonstrate p53-dependent MIC-1 activation by both D and the MDM2 inhibitor RG7112. This study evaluated the tolerability of combining D with RG7112 in ASTS patients (pts) and pharmacokinetic (PK) and pharmacodynamic (PD) parameters of the combination. Methods: A phase 1b 3+3 dose escalation study was designed. Pts with ASTS in whom D was considered appropriate were eligible. D was administered IV at either 50 mg/m2 or 60 mg/m2on day 1 with RG7112 administered orally 500 or 1000 mg QD for 3 or 5 days (d1-3 or d1-5) in 28-d treatment cycles. Safety, PK and PD, including serum MIC-1 (an indicator of p53 activation), were assessed. Results: As of January 15, 2013, enrollment was complete with 23 pts with ASTS accrued; safety data for cycle 1 was available for preliminary review in 20 pts. Growth factor support was mandated following the first dosing group (D 60 mg/m2and RG7112 500 mg x 5d) due to febrile neutropenia or grade 4 neutropenia. Of the 20 pts for which cycle 1 safety data is available, 13 pts reported neutropenia (12 grade 3/4); 5 reported grade 3/4 febrile neutropenia (3 following mandatory GCSF prophylaxis); 12 pts developed thrombocytopenia (9 grade 3/4). PK parameters of the combination therapy are similar to single agent values and did not demonstrate evidence of drug-drug interactions. Serum MIC-1 rapidly increased to levels greater than for either agent alone. Best response to date is stable disease in 8/16 pts who have had interim evaluations. Conclusions: Combination therapy with D and RG7112 resulted in a high rate of grade 3/4 neutropenia (60%) or thrombocytopenia (45%). PK analysis does not suggest this is due to changes in the metabolism of either drug. This combination demonstrates apparent potentiation of p53 activation demonstrated by increased MIC-1 levels greater than additive effects of the single agents. Biomarker analyses, safety, PK, and MIC-1 data will be presented. Clinical trial information: NCT01605526. [Table: see text]
Collapse
Affiliation(s)
| | - Jean-Yves Blay
- University Claude Bernard Lyon I, Centre Léon Bérard, Lyon, France
| | | | | | | | | | - Launce G. Gouw
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | | | | | - Brian Higgins
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, Nutley, NJ
| | - Steven Middleton
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, Nutley, NJ
| | - Gwen L. Nichols
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, Nutley, NJ
| | - David Geho
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, Nutley, NJ
| | - Steven Blotner
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Nutley, NJ
| | - Jianguo Zhi
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Nutley, NJ
| | - Lin Chi Chen
- Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, Nutley, NJ
| |
Collapse
|
33
|
Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss G, Nichols G, Middleton S, Sarapa N, Beryozkina A, Zhi J. Abstract LB-201: Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-lb-201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MDM2 is overproduced as a mechanism to impair p53 function in many cancers. By reactivating p53, antagonists of p53-MDM2 interaction could offer a novel approach to treatment of solid tumors and leukemias. RG7112, the first potent and selective small-molecule MDM2 antagonist in clinical testing, is an oral p53 activator and is currently in phase I. To optimize its dose and schedule, a number of clinical pharmacology characteristics were explored in this multi-center trial in patients (pts) with advanced solid tumors. In Part I, the impact of high-energy/high-fat meal and formulation (crystalline versus amorphous) was examined in cross-over design. In Part II, schedule optimization (4 schedules of drug adm under fasting condition and 1 cohort with liquid supplementation) was investigated in parallel, dose escalation design. Clinical endpoints were PK/PD and safety/tolerability including platelet reduction (a potential target-mediated hematological toxicity indicator).
A total of 76 pts (42F and 34M, mean age 60 yr) participated in the study. In their first-cycle treatment, 36 pts received weekly x3 (26 with food/formulation evaluation), 15 pts daily x5, 6 pts daily x20, and 19 pts daily x3 (3 with food evaluation) doses; daily doses ranged from 500-4500 mg. The most commonly reported AEs (> 20%) were GI-related. Twelve pts have reported 21 SAEs, of which, 4 events in 2 pts (1 pt with G4 thrombocytopenia, anemia, and neutropenia; 1 pt with G3 delirium) were related to study treatment.
A high-energy (∼1000 kcal)/high-fat (∼60 g) meal and a reduced energy (∼500 kcal)/fat (∼30 g) liquid supplementation both enhanced overall bioavailability (BA) of tested formulations by 2-fold, with inter-pt variability reduced by half. At steady-state, amorphous formulation also reduced PK variability by half from the crystalline formulation. High-dose consecutive daily dosing for 5 and 3 d yielded highest drug concentrations on the last day of treatment. On the other hand, both weekly and low-dose/long-duration (20-day) schedules yielded lower peak concentrations (note that the per-cycle exposure was comparable to, or higher than, high-dose 5x and 3x daily schedules).
Serum profiles of MIC-1, a secreted protein that is strongly induced by activated p53, showed similar patterns to the PK when the clinical pharmacology conditions were varied.
The first-cycle platelet profiles indicate that the weekly schedule didn't cause platelet reduction, while the daily schedules showed a trend of dose- and length-dependent platelet reduction with daily x 5 at high doses being the most pronounced (1 pt resulted in G-4 thrombocytopenia).
In conclusion, RG7112 is well tolerated with or without food in the therapeutically relevant dose range, food enhanced BA with reduced variability, and high-dose consecutive daily for 3-5 d is superior in yielding sufficiently high PK exposure and PD effects potentially required for cancer treatment efficacy.
Citation Format: Amita Patnaik, Anthony Tolcher, Muralidhar Beeram, John Nemunaitis, Glen Weiss, Gwen Nichols, Steven Middleton, Nenad Sarapa, Anna Beryozkina, Jianguo Zhi. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-201. doi:10.1158/1538-7445.AM2013-LB-201
Collapse
|
34
|
Daly AL, Robertson A, Johnson P, Middleton S, Bobek G, Sullivan C, Hennessy A. PP162. sFlt-1 controlled by CPAP in a pregnant patient with chronic hypertension. Pregnancy Hypertens 2012; 2:327. [PMID: 26105483 DOI: 10.1016/j.preghy.2012.04.273] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Preeclampsia is recognised as the leading cause of perinatal mortality and morbidity worldwide. Interest has been increasing recently as to the possible impact of sleep disordered breathing (SDB) on the mechanisms of preeclampsia, possibly by augmenting placental hypoxia during sleep. A biomarker of preeclampsia, sFlt-1, has also come to prominence in recent years and is postulated to be a good predictor of preeclampsia as well as a strong indicator of the severity of the disease. OBJECTIVES The aim of this study was to investigate the effect of CPAP treatment for SDB on sFlt-1 concentrations during pregnancy. METHODS Patients were recruited from the outpatients' clinic in Campbelltown Hospital, Campbelltown, NSW in the first half of 2011. The levels of sFlt-1 in four pregnant women, with or without hypertensive disorders of pregnancy, and with or without SDB were measured using ELISA. RESULTS Women with SDB and chronic hypertension or preeclampsia had higher levels of sFlt-1 and a greater percentage increase of this marker, and CPAP treatment appeared to attenuate the rise of sFlt-1 as shown in the table below. CONCLUSION Elevated sFlt-1 was associated with untreated SDB in those with chronic hypertension. This study provides feasibility for a larger scale study to occur, to further examine the validity of the hypothesis that CPAP treatment has a beneficial effect on sFLt-1 levels and therefore, may lower the risk and severity of preeclampsia.
Collapse
Affiliation(s)
- A L Daly
- University of Western Sydney, Sydney, Australia
| | - A Robertson
- University of Western Sydney, Sydney, Australia
| | - P Johnson
- Sleep Medicine, University of Sydney, Sydney, Australia
| | | | - G Bobek
- University of Western Sydney, Sydney, Australia
| | | | - A Hennessy
- University of Western Sydney, Sydney, Australia
| |
Collapse
|
35
|
Robertson A, Johnson P, Thornton C, Whitton AM, Middleton S, Sullivan C, Hennesssy A. PP154. Relationship between recorded and reported snoring during pregnancy: Objective measurement versus questionnaire responses. Pregnancy Hypertens 2012; 2:322. [PMID: 26105475 DOI: 10.1016/j.preghy.2012.04.265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Snoring is a common symptom of sleep disordered breathing (SDB), a condition that is present in 4% of the general population. SDB is identified by snoring and repetitive cessation of breathing during sleep accompanied by repetitive hypoxia and has been found to be associated with hypertension, stroke and heart attack. There is not depth of knowledge examining the association between SDB and pregnancy outcomes. OBJECTIVES To examine the prevalence of self reported snoring in pregnancy and the potential association between self reported snoring and the development of Hypertensive Disorders of Pregnancy (HDP) within a larger cohort from a prevalence of SDB in pregnancy study. METHODS Questionnaires were administered to pregnant women attending an outpatient's antenatal clinic. The self reported snoring is a component of the Epworth scale. Pregnancy progression and outcome data were collected on all participants and analyse by IBM SPSS v.20™ utilising Chi-square analysis, Student T test and logistic regression analysis. HDP diagnoses were in alignment with the SOMANZ (2009) diagnostic criteria. RESULTS Questionnaires were administered and outcomes collected on 2023 pregnancies. Snoring was reported by 49.2% of women. HDP affected 10.1% of the cohort, 3.3% of whom were preeclamptic. Of the pregnancies affected by HDP self reported snoring occurred in 57.7% in comparison to 43.3% who do not report snoring (p<0.001). CONCLUSION This would indicate that there is an association between self reported snoring and the development of HDP. Further analysis will be undertaken to model the effect of other potential risk factors such as maternal age, parity, pre-pregnancy BMI and other co morbidities.
Collapse
Affiliation(s)
- A Robertson
- Medicine, University of Western Sydney, Australia; Medicine, South Western Sydney Local Health District, Campbelltown, Australia
| | - P Johnson
- Medicine, University of Sydney, Australia
| | - C Thornton
- Medicine, University of Western Sydney, Australia
| | - A-M Whitton
- Medicine, University of Western Sydney, Australia
| | | | - C Sullivan
- Medicine, University of Sydney, Australia
| | - A Hennesssy
- Medicine, University of Western Sydney, Australia; Medicine, South Western Sydney Local Health District, Campbelltown, Australia; Vascular Immunology Group, Heart Research Institution, Sydney, Australia
| |
Collapse
|
36
|
Wright L, Hill KM, Bernhardt J, Lindley R, Ada L, Bajorek BV, Barber PA, Beer C, Golledge J, Gustafsson L, Hersh D, Kenardy J, Perry L, Middleton S, Brauer SG, Nelson MR. Stroke management: updated recommendations for treatment along the care continuum. Intern Med J 2012; 42:562-9. [DOI: 10.1111/j.1445-5994.2012.02774.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Kurzrock R, Blay JY, Bui Nguyen B, Wagner AJ, Maki RG, Schwartz GK, Patnaik A, Gore L, Wu L, Vassilev LT, Ding M, Geho D, Zhi J, Middleton S, Nichols GL. A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e13600] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13600^ Background: RG7112 is a small molecule MDM2 antagonist, designed to non-genotoxically activate p53. A phase I dose escalation (DE) was performed, followed by a sarcoma biomarker extension (EXT) in pts with wild type TP53. Methods: 106 pts (58M, 48 F), median age 57.9 yrs (range 22-84) participated; 76 in 9 cohorts (DE) from 20 to 1800 mg/m2, orally QD x 10 q28 days. 30 pts with sarcoma were treated at MTD (2500 mg) (EXT) with pre-and on dose (d5+/-2) biopsies. Analyses included TP53 mutation (AmpliChip), MDM2 amplification (ISH), p53 and p21 IHC, MDM2 RT-PCR, Ki-67, TUNEL and [18F]-FLT-PET. Blood was obtained for PK and MIC-1, a PD marker of p53 activation. Results: DE: MTD was1440 mg/m2/d (2500 mg flat dose). PK was ~dose linear (t½ 1-1.5 d) with high variability (CV~70%) in AUC and Cmax . Adverse events included nausea/GI and exposure-related neutropenia/thrombocytopenia. 3 DLTs: diarrhea, pancytopenia, hyponatremia occurred (at ≥ 640 mg/m2). Evidence of activity included: 1) concentration dependent increase in plasma MIC-1 (% baseline), 2) decrease in [18F]-FLT PET and PR each in liposarcoma pts at 1800 mg/m2 and 1440 mg/m2, respectively. EXT: Grade3/ 4 cytopenias at MTD precluded subsequent cycles in 6/8 pts (10 day schedule). Dosing was changed to 5 days, and only 3 patients had Gr3/4 cytopenias. 8/22 pts remained on study for >4 cycles, including 2 pts with SD for 7 and 9 cycles respectively. 3 of 4 EXT pts had decreased [18F]-FLT-PET activity. Biopsies (pre- and on treatment) demonstrated: 1) increase in p53 (median 1.5 fold change (X) by IHC, n=15); 2) increase in p21 (median 2.7X by IHC, n=14); 3) increase in MDM2 (median 2.5X by RT-PCR, n = 27); 4) decrease in % Ki-67(+) cells (median % change from baseline -65.4%, range -91% to +275%, n=17 ); 5) increase in TUNEL(+) cells of 9.0 (density of + cells/mm2, range -26.2 to +45.5, n=22). These results were seen both in tumors with and without MDM2 gene amplification, and in multiple sarcoma subtypes. Conclusions: RG7112 has manageable AEs (GI ) and cytopenias correlating with AUC. Single agent disease control, and biomarker activity was seen in both MDM2 amplified and non-amplified, heavily pretreated soft tissue sarcoma pts, with changes reflecting activation of p53-related pathways.
Collapse
Affiliation(s)
- Razelle Kurzrock
- Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | - Robert G. Maki
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - Amita Patnaik
- South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX
| | - Lia Gore
- University of Colorado Cancer Center, Aurora, CO
| | - Lin Wu
- Roche Molecular Systems, Pleasanton, CA
| | | | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Nestel PJ, Pally S, MacIntosh GL, Greeve MA, Middleton S, Jowett J, Meikle PJ. Circulating inflammatory and atherogenic biomarkers are not increased following single meals of dairy foods. Eur J Clin Nutr 2011; 66:25-31. [DOI: 10.1038/ejcn.2011.134] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
40
|
Abstract
OBJECTIVES To investigate risk factors associated with cranial cruciate ligament rupture in dogs. METHODS Retrospective case-control study: medical records of a first-opinion veterinary practice were searched for dogs diagnosed with cranial cruciate ligament rupture (1995 to 2007). For each case, six unaffected dogs were randomly selected from all dogs presenting that day for comparison. Multi-variable binary logistic regression was performed to assess the association of variables on likelihood of cruciate rupture. RESULTS Frequency of cranial cruciate ligament rupture was 1·19% [95% confidence interval (CI) 1·02 to 1.36%]. West Highland white terriers (n=17), Yorkshire terriers (n=14) and Rottweilers (n=11) were at significantly increased risk of cranial cruciate ligament rupture (P≤0·002). Rottweilers were at five times greater risk compared with other pure breeds (OR 5·12, 95% CI 2·281 to 11·494, P<0·001), obesity quadrupled the risk of cranial cruciate ligament rupture (OR 3·756, 95% CI 1·659 to 8·502, P=0·001) and females were twice as likely to suffer cranial cruciate ligament failure compared to males (OR 2·054, 95% CI 1·467 to 2·877, P<0·001). Dogs less than two years old were statistically less likely to sustain cranial cruciate ligament rupture than dogs older than eight years (OR 0·246, 95% CI 0·127 to 0·477, P<0·001). There was no significant difference in median weights (in kilograms) of neutered dogs, compared to their entire counterparts in either the case group (P=0·994) or in the control group (P=0·630). There was also no significant difference in body condition (-underweight/normal weight/overweight/obese) of neutered versus entire dogs among the cases (P=0·243), or the controls (P=0·211). CLINICAL SIGNIFICANCE Cranial cruciate ligament rupture is more likely in Rottweilers and in female dogs, older dogs and obese dogs. Following multi-variable analysis, it was established that neutering was not associated with increased risk of cranial cruciate ligament rupture.
Collapse
Affiliation(s)
- P Adams
- PDSA PetAid Hospital, 5 Club Street, London Road, Stoke-on-Trent, Staffordshire ST4 5RQ, UK
| | | | | | | | | |
Collapse
|
41
|
Beryozkina A, Nichols GL, Reckner M, Vassilev LT, Rueger R, Jukofsky L, Middleton S, Andreeff M, Padmanabhan S, Strair R, Delioukina ML, Maslak PG, Hillmen P, Kurzrock R, Gore L, Patnaik A, Maki RG, Schwartz GK, Wagner AJ, Zhi J. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
|
43
|
Middleton S, Levi C, Ward J, Grimshaw J, Griffiths R, D'Este C, Dale S, Quinn C, Evans M, Cadilhac D, McElduff P. Death, dependency and health status 90 days following hospital admission for acute stroke in NSW. Intern Med J 2010; 41:736-43. [DOI: 10.1111/j.1445-5994.2010.02330.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Mitchell L, Archer E, Middleton S, Maclean A, Jones L, Benger J, Lloyd G. Paediatric distal radial fracture manipulation: multicentre analysis of process times. Emerg Med J 2009; 26:41-2. [DOI: 10.1136/emj.2007.057208] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Li S, Chiu G, Pulito V, Liu J, Connolly P, Middleton S. Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors. Med Chem 2009; 5:15-22. [DOI: 10.2174/157340609787049280] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
46
|
Middleton S, Jalics J, Kispersky T, LeBeau FEN, Roopun AK, Kopell NJ, Whittington MA, Cunningham MO. NMDA receptor-dependent switching between different gamma rhythm-generating microcircuits in entorhinal cortex. Proc Natl Acad Sci U S A 2008; 105:18572-7. [PMID: 18997013 PMCID: PMC2587538 DOI: 10.1073/pnas.0809302105] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2008] [Indexed: 12/20/2022] Open
Abstract
Local circuits in the medial entorhinal cortex (mEC) and hippocampus generate gamma frequency population rhythms independently. Temporal interaction between these areas at gamma frequencies is implicated in memory-a phenomenon linked to activity of NMDA-subtype glutamate receptors. While blockade of NMDA receptors does not affect frequency of gamma rhythms in hippocampus, it exposes a second, lower frequency (25-35 Hz) gamma rhythm in mEC. In experiment and model, NMDA receptor-dependent mEC gamma rhythms were mediated by basket interneurons, but NMDA receptor-independent gamma rhythms were mediated by a novel interneuron subtype-the goblet cell. This cell was distinct from basket cells in morphology, intrinsic membrane properties and synaptic inputs. The two different gamma frequencies matched the different intrinsic frequencies in hippocampal areas CA3 and CA1, suggesting that NMDA receptor activation may control the nature of temporal interactions between mEC and hippocampus, thus influencing the pathway for information transfer between the two regions.
Collapse
Affiliation(s)
- Steven Middleton
- Institute of Neuroscience, Newcastle University, Newcastle NE2 4HH, United Kingdom
| | - Jozsi Jalics
- Department of Mathematics and Statistics, Youngstown State University, One University Plaza, Youngstown, OH 44555
| | - Tilman Kispersky
- Program in Neuroscience, Center for BioDynamics, Boston University, Boston, MA 02215; and
| | - Fiona E. N. LeBeau
- Institute of Neuroscience, Newcastle University, Newcastle NE2 4HH, United Kingdom
| | - Anita K. Roopun
- Institute of Neuroscience, Newcastle University, Newcastle NE2 4HH, United Kingdom
| | - Nancy J. Kopell
- Department of Mathematics and Statistics, Center for BioDynamics, 111 Cummington Street, Boston University, Boston, MA 02215
| | - Miles A. Whittington
- Institute of Neuroscience, Newcastle University, Newcastle NE2 4HH, United Kingdom
| | - Mark O. Cunningham
- Institute of Neuroscience, Newcastle University, Newcastle NE2 4HH, United Kingdom
| |
Collapse
|
47
|
Fuchs EC, Zivkovic AR, Cunningham MO, Middleton S, Lebeau FEN, Bannerman DM, Rozov A, Whittington MA, Traub RD, Rawlins JNP, Monyer H. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 2008; 53:591-604. [PMID: 17296559 DOI: 10.1016/j.neuron.2007.01.031] [Citation(s) in RCA: 379] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2005] [Revised: 08/28/2006] [Accepted: 01/29/2007] [Indexed: 10/23/2022]
Abstract
Perisomatic inhibition provided by a subgroup of GABAergic interneurons plays a critical role in timing the output of pyramidal cells. To test their contribution at the network and the behavioral level, we generated genetically modified mice in which the excitatory drive was selectively reduced either by the knockout of the GluR-D or by conditional ablation of the GluR-A subunit in parvalbumin-positive cells. Comparable cell type-specific reductions of AMPA-mediated currents were obtained. Kainate-induced gamma oscillations exhibited reduced power in hippocampal slices from GluR-D-/- and GluR-A(PVCre-/-) mice. Experimental and modeling data indicated that this alteration could be accounted for by imprecise spike timing of fast-spiking cells (FS) caused by smaller interneuronal EPSPs. GluR-D-/- and GluR-A(PVCre-/-) mice exhibited similar impairments in hippocampus-dependent tasks. These findings directly show the effects of insufficient recruitment of fast-spiking cells at the network and behavioral level and demonstrate the role of this subpopulation for working and episodic-like memory.
Collapse
Affiliation(s)
- Elke C Fuchs
- Department of Clinical Neurobiology, University Hospital of Neurology, IZN, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bibbig A, Middleton S, Racca C, Gillies MJ, Garner H, Lebeau FEN, Davies CH, Whittington MA. Beta rhythms (15-20 Hz) generated by nonreciprocal communication in hippocampus. J Neurophysiol 2007; 97:2812-23. [PMID: 17287437 DOI: 10.1152/jn.01105.2006] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Generation of gamma rhythms in reciprocally connected areas of cortex produces synchronous neuronal firing, although little is known about the consequences of gamma rhythms when generated in nonreciprocally connected regions. This nonreciprocity exists in hippocampus, where gamma rhythms are generated in area CA3 in vitro and in vivo and nonreciprocally projected to area CA1 by the Schaffer collateral pathway. Here we demonstrate how this CA3 gamma rhythm generates two different patterns of local CA1 oscillation dependent on the degree of output from area CA1. 1) In conditions where activity projected to area CA1 produces only very low principal cell recruitment the local population rhythm mimics the gamma rhythm projected from CA3. This activity is generated predominantly by recruitment of CA1 basket cells in a manner dependent on phasic, feedforward excitation of this interneuron subclass. Interneurons in stratum oriens, not receiving CA3 feedforward input, fired at theta frequencies. 2) In the presence of serotonin CA1 principal cell recruitment was appreciably enhanced, resulting in dual activation of CA1 basket cells through both feedforward and feedback excitations. Feedback excitation to CA1 stratum oriens interneurons was also enhanced. The resulting change in interneuron network dynamics generated a beta-frequency CA1 rhythm (as a near-subharmonic of the gamma rhythm projected from CA3). These findings demonstrate that in nonreciprocally connected networks, the frequency of population rhythms in target areas serves to code for degree of principal cell recruitment by afferent input.
Collapse
Affiliation(s)
- Andrea Bibbig
- Department of Physiology and Pharmacology, State University of New York Health Sciences Center, Brooklyn, New York, USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Cunningham MO, Hunt J, Middleton S, LeBeau FEN, Gillies MG, Davies CH, Maycox PR, Whittington MA, Racca C. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 2006; 26:2767-76. [PMID: 16525056 PMCID: PMC6675154 DOI: 10.1523/jneurosci.5054-05.2006] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Psychiatric illnesses, particularly schizophrenia, are associated with disrupted markers for interneuronal function and interneuron-mediated brain rhythms such as gamma frequency oscillations. Here we investigate a possible link between these two observations in the entorhinal cortex and hippocampus by using a genetic and an acute model of psychiatric illness. Lysophosphatidic acid 1 receptor-deficient (LPA1-deficient) mice show psychomotor-gating deficits and neurochemical changes resembling those seen in postmortem schizophrenia studies. Similar deficits are seen acutely with antagonism of the NMDA subtype of glutamate receptor. Neither model induced any change in power or frequency of gamma rhythms generated by kainate in hippocampal slices. In contrast, a dramatic decrease in the power of gamma oscillations was seen in superficial, but not deep, medial entorhinal cortex layers in both models. Immunolabeling for GABA, parvalbumin, and calretinin in medial entorhinal cortex from LPA1-deficient mice showed an approximately 40% reduction in total GABA- and parvalbumin-containing neurons, but no change in the number of calretinin-positive neurons. This deficit was specific for layer II (LII). No change in the number of neurons positive for these markers was seen in the hippocampus. Acute NMDA receptor blockade, which selectively reduces synaptic drive to LII entorhinal interneurons, also disrupted gamma rhythms in a similar manner in superficial entorhinal cortex, but not in hippocampus. These data demonstrate an area-specific deficit in gamma rhythmogenesis in animal models of psychiatric illness and suggest that loss, or reduction in function, of interneurons having a large NMDA receptor expression may underlie the network dysfunction that is seen.
Collapse
|
50
|
Middleton S, Goli A, Ziarani AK. A software module for the adaptive estimation of steady state auditory evoked potentials. Conf Proc IEEE Eng Med Biol Soc 2006; 2006:3700-3703. [PMID: 17945789 DOI: 10.1109/iembs.2006.260653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A graphical user interface (GUI) implementing a novel technique of fast estimation of steady state auditory evoked potentials (SSAEPs) for rapid assessment of the functionality of the human auditory nervous system is presented. The proposed signal estimator has shown great promise in the fast extraction of weak signals buried under large amounts of noise such as the case with SSAEP signals. Currently, the main technical impediment in the widespread clinical use of the SSAEP testing for hearing assessment is the excessively long measurement time needed for the estimation process due to the presence of large amounts of background noise. The presented software module that is publicly disseminated through the Internet is meant to facilitate the use of an efficient signal processing technique by the hearing researchers. The software environment allows for loading previously recorded SSAEP signals into the workspace for analysis. Moreover, it enables the user to add simulated SSAEP signals to the background EEG for the purpose of testing the capability of the underlying signal processing algorithm.
Collapse
Affiliation(s)
- S Middleton
- Dept. of Electr. & Comput. Eng., Clarkson Univ., Potsdam, NY 13699, USA
| | | | | |
Collapse
|